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ABSTRACT 
   
 Biosensors offer excellent diagnostic methods through precise 
quantification of bodily fluid biomarkers and could fill an important niche in 
diagnostic screening. The long term goal of this research is the development of 
an impedance immunosensor for easy-to-use, rapid, sensitive and selective 
simultaneously multiplexed quantification of bodily fluid disease biomarkers. To 
test the hypothesis that various cytokines induce empirically determinable 
response frequencies when captured by printed circuit board (PCB) impedance 
immunosensor surface, cyclic voltammetry (CV) and electrochemical impedance 
spectroscopy (EIS) methods were used to test PCB biosensors versus multiple 
cytokine biomarkers to determine limits of detection, background interaction and 
response at all sweep frequencies. Results indicated that sensors for cytokine 
Interleukin-12 (IL-12) detected their target over three decades of concentration 
and were tolerant to high levels of background protein. Further, the hypothesis 
that cytokine analytes may be rapidly detected via constant frequency impedance 
immunosensing without sacrificing undue sensitivity, CV, EIS, impedance-time 
(Zt) methods and modeling were used to test CHI™ gold electrodes versus IL-12 
over different lengths of time to determine limits of detection, detection time, 
frequency of response and consistent cross-platform sensor performance. 
Modeling and Zt studies indicate interrogation of the electrode with optimum 
frequency could be used for detection of different target concentrations within 90 
seconds of sensor exposure and that interrogating the immunosensor with fixed, 
optimum frequency could be used for sensing target antigen. This informs 
usability of fixed-frequency impedance methods for biosensor research and 
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particularly for clinical biosensor use. Finally, a multiplexing impedance 
immunosensor prototype for quantification of biomarkers in various body fluids 
was designed for increased automation of sample handling and testing. This 
enables variability due to exogenous factors and increased rapidity of assay with 
eased sensor fabrication. Methods were provided for simultaneous multiplexing 
through multisine perturbation of a sensor, and subsequent data processing. This 
demonstrated ways to observe multiple types of antibody-antigen affinity binding 
events in real time, reducing the number of sensors and target sample used in 
the detection and quantification of multiple biomarkers. These features would 
also improve the suitability of the sensor for clinical multiplex detection of disease 
biomarkers.  
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CHAPTER 1 
INTRODUCTION 
1.1 Overview 
 United States health care costs associated with diagnosis almost tripled 
between 2000 and 2008, from $90 billion to $250 billion (Feldman 2009), far 
exceeding the velocity of overall health care costs, which took from 1990 to 2008 
to triple from $714 billion to $2.3 trillion as shown in Fig. 1.1 (NHSG 2010). This 
excess expenditure is driven by the continuing transition from screening by 
primary physician to expensive and powerful laboratory tests (Feldman 2009). 
Increasing costs of diagnosis highlight the need for inexpensive equipment and 
operations, even when controlling for overall increased medical expenditures. 
Moreover, the prevention and therapeutic treatment of many diseases would be 
improved by early detection. Early detection can come from both improved 
accuracy and sensitivity of methods and from low cost and ease of use, traits 
which also improve the device‟s suitability in a monitoring capacity. Many 
diseases may be diagnosed and monitored through the quantification of bodily 
fluid biomarkers. Biosensors offer excellent methods for the precise quantification 
of bodily fluid biomarkers.  
 Combining a biological or biomimetic element with a signal transducer, 
biosensors were first and remain foremost employed in blood glucose 
quantification for diabetes monitoring (Clark 1962; Lowe 2008A). Biosensors 
have also found application in: monitoring the environment (Amine et al. 2006); 
spread of infectious disease (Spielbauer and Stahl 2005), genetic profiling for 
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personalized medicine (Blouin et al. 1996); increasing drug discovery throughput 
by rapid secondary screening of biopharmaceutical candidates (Shamah and 
Cunningham 2011); explosives detection for counterterrorism purposes (Smith et 
al. 2008); and quantification of disease biomarkers (Rapp et al. 2010). The 
characteristics of the many kinds of biosensors vary, and may be selected to 
meet the particular demands of the diagnostics market.  
 
Fig. 1.1 Annual Rate of Increase for US Healthcare Costs 2000-2008: The annual rate of increase 
for diagnosis costs in the US was more than double the rate of the overall medical cost increase 
(Feldman 2009; NHSG 2010). 
1.2 Significance 
 The long term goal of this research is the development of a 
multifrequency impedance immunosensor for easy-to-use, cheap, rapid, sensitive 
and selective simultaneous multiplexed quantification of bodily fluid disease 
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biomarkers. This will be accomplished through experimental determination of 
important sensor parameters. 
 
Fig. 1.2 Diagnostic Strength vs Convenience:  Symptom screening by a primary physician and 
other similarly basic diagnostic methods have relatively low diagnostic strength, but are 
comparatively easy and convenient to perform. Intensive laboratory diagnostic tests have relatively 
high diagnostic strength, but are comparatively less easy and convenient to perform. Point-of-Care 
disease biomarker biosensors have the potential to fit in the diagnostic niche between initial 
screening and exhaustive analysis, with „good enough‟ diagnostic strength and convenience, ease, 
and speed of testing.  
 
 Diagnosis and monitoring of many diseases (and biomarker quantification 
in much disease research) relies on techniques that could be surpassed. Bodily 
fluid biomarkers are a promising avenue for disease prediction, monitoring, and 
diagnosis, and scientific research of disease states, and have a ready niche 
between primary disease screening and intensive laboratory testing, as 
illustrated in Fig. 1.2. In many cases, the rapidly growing library of disease-
relevant biomarkers may be used to diagnose disease in earlier stages, or 
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diagnose the disease more accurately and precisely than current disease 
diagnostic methods.  
1.2.1 Cytokine Biomarkers 
 Cytokines, which are a coherent subset of circulating biomarkers, are 
critical components of the immune system, and are circulating biomarkers for 
many disease states. Cytokine biomarkers have been found for many cancers, 
including those of the thyroid (Interleukin (IL)-5, IL-8 and IL-12p40) (Linkov et al. 
2008), breast (IL-6 and IL-8) (Nolen et al. 2008) and prostate (Transforming 
Growth Factor (TGF) 1 and IL-6) (Steuber et al. 2007). The cytokines IL-6, 
Tumour Necrosis Factor (TNF)-α, IL-18 (Armstrong et al. 2006), and IL-10 
(Vasan 2006) serve as biomarkers of acute coronary syndromes. Cytokines are 
predictive of multiple organ failure resulting from trauma, including IL-6 and 
sTNF-R (Maier et al. 2007).  
Bodily fluid cytokines have functional implications in autoimmune 
syndromes and diseases with suspected autoimmune components, and therefore 
they may serve as biomarkers of those diseases. For multiple sclerosis, they 
include IL-1β, Il-2, Il-6, IL-10, IL-12, interferon-gamma (IFN-γ), and TNF-α 
(Giovannoni et al. 1997; Hollifield et al. 2003; Nicoletti et al. 1996; Woodroofe et 
al. 1991). For rheumatoid arthritis, cytokine biomarkers include IL-1B, TNF-α, and 
IL-6 (Hueber et al. 2009; Rioja et al. 2004). Cytokine biomarkers for irritable 
bowel syndrome include IL-6, IL-8, IL-1B and TNF-α (Scully et al. 2010), and for 
inflammatory bowel disease (IBD) could include IL-1 , IL-4, IL-6, IL-12, IL-17, 
TNF-α and INF-γ (Alex et al. 2009; Alex 2008). For systemic lupus 
erythematosus (SLE), they include IL-2, IL-6 and IL-10 (Chun et al. 2007). In 
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stages of organ rejection, they include TNF-α (Platz et al. 1996), IL-6 and IL-10 
(Hassan et al. 2006).  
 The potential efficacy of bodily fluid biomarker evaluation should be 
compared to current disease diagnostic State of the Art (SOTA), with reference 
to not just the sensitivity and selectivity, but also assay time, expense, and 
convenience.  
1.2.2 Diagnostic State of the Art.  
 Sensitivity and selectivity should not be the only factors considered in 
diagnosis. The earlier the stage of the disease detected, or the earlier the 
prediction of the disease, the more useful the diagnostic method, as mitigation or 
prevention efforts are best implemented as early as possible.  
 Current SLE referral and diagnosis requires 3 or 4 of 11 possible 
exhibited symptoms to have occurred, some of which require laboratory 
assessment, for 95% specificity and 85% selectivity. Diagnosis can be 
problematic and uncertain, but of course early diagnosis is important for good 
outcomes. After diagnosis, lifelong monitoring is required for disease 
management, the alternative being poorer immediate health and greater 
permanent organ damage. This monitoring involves a great amount and variety 
of laboratory diagnostics and in-person medical labor (Gladman et al. 1999). 
Though there have been no updates to the official SLE diagnostic criteria since 
1997 (Hochberg 1997), minor revisions have been proposed (Feletar et al. 2003; 
Liang 2004). This leaves an opportunity for improvement via testing of diagnostic 
and prognostic bodily fluid biomarkers with inexpensive, easy to use biosensors.  
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 As an example, Crohn‟s disease (CD), a form of IBD, exhibits as a series 
of attacks that cause permanent damage to the intestines. Early detection could 
reduce this debilitating damage by averting and mitigating attacks (Campieri 
2002). There is no specific diagnostic test for CD in the standard criteria, and no 
protein biomarkers in clinical use. Standard criteria include a laborious process of 
elimination of similarly exhibiting syndromes, and expensive radiocolonoscopy 
(Glickman 1994). Histological examination of colon bioposies without reference 
to clinical details distinguishes IBD tissue from normal tissue with 82% sensitivity 
and 99% specificity, and ulcerative colitis tissue from CD with 61% sensitivity and 
76% specificity (Cross and Harrison 2002), though biopsy would normally only 
occur after manifestation of symptoms. The fact that a combination of 
haemoglobin and platelet count yielded 90.8% sensitivity and 80% specificity for 
patients already complaining of possible IBD symptoms (Cabrera-Abreu et al. 
2004) reveals the potential for using bodily fluid biomarkers to ease diagnosis of 
this syndrome. 
1.3 Rationale 
 Among biosensors are many promising devices that could be used for 
quantification of bodily fluid biomarkers. These include surface plasmon 
resonance (SPR) techniques, piezoelectric techniques including cantilever and 
quartz crystal microbalance (QCM), optical techniques and electrochemical 
techniques like Electrochemical Impedance Spectroscopy (EIS). All of these 
have their advantages and disadvantages. SPR is a very sensitive measurement 
technique, but often demands lengthy optimization and requires expensive, 
complicated instrumentation. The technique is also vulnerable to interference 
7 
 
signal from non-specific surface–analyte interactions, has a narrow dynamic 
range compared to electrochemical techniques, and can generate poor signals 
for small molecules (Jecklin et al. 2009; Ramirez et al. 2009). QCM biosensors 
offer a direct measurement of mass adhered to the device, but have lower 
sensitivity limits in the range of μg/ml (Marx 2003), far too insensitive for clinical 
ranges of many biomarkers. Optical techniques are very widely relied upon, 
usually utilize amplification and secondary labeling steps, increasing expense 
and decreasing ease of use.  
 As a biosensing technique, EIS has been used for biomarker detection 
and quantification of disease biomarkers. However, this has often involved long 
incubation times, or less sensitivity than required for evaluation of biomarkers at 
clinically relevant levels (Degefa and Kwak 2008; Du et al. 2008; Evans et al. 
2008; Min et al. 2008; Navratilova and Skladal 2004; Rahman et al. 2007; Rickert 
et al. 1996; Tsai et al. 2011; Yang et al. 2007). In many instances, complicated 
labeling schemes were employed, which raises assay duration and cost, and 
make real-time monitoring impossible. The increased complication makes 
sensors less suitable for point-of-care applications (Rapp et al. 2010). Without 
any secondary labeling or signal amplification, using biosensor detection reduces 
time, is lower-cost and is less complicated. Simultaneous detection of different 
metal ions has been theorized, but the technique does not have cross-
applicability to label free protein affinity detection (Lindholm-Sethson et al. 2003). 
EIS biosensor arrays exist (Fairchild et al. 2009; Pan et al. 2010; Sadik et al. 
2009), as do multisine EIS systems utilizing convoluted waveforms to simulate an 
EIS frequency sweep in a reduced period of time (Blajiev et al. 2006; Creason 
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and Smith 1972). However, a system for mass simultaneous multiplexing using 
AC impedance biosensing has not yet been implemented, leaving interrogation of 
a single sensor with a single convoluted waveform over a period of time a 
potentially superior alternative to multiple sensors interrogated by multiple 
potentiostats. 
1.4 Objectives  
 Ideal detection frequencies, once found, can be employed in real-time 
monitoring of the impedance response, as well as the use of one biosensor for 
multiple target concentrations via a multifrequency convoluted signal. By 
modeling the kinetics of antibody-antigen interaction on the biosensor surface 
and quantifying the impedance response over time, an acceptable minimum 
detection time can be determined. By empirically determining the frequency of 
response for multiple cytokines versus their respective antibodies, the design of a 
simultaneous multiplexing device may be accomplished.  
 In this dissertation I present three studies in impedance immunosensing 
that address my long term objectives. The first study presents the results of 
testing a printed circuit board (PCB) EIS immunosensor versus multiple 
cytokines, establishing critical criteria such as frequency of response. The 
second study presents the results of testing gold disk impedance immunosensors 
versus cytokine biomarkers in real time, determining affinity kinetic model of 
antigen-antibody association and minimum detection time of the system, and 
confirming robustness of results cross-platform. The third study presents the 
feasibility of a multiplexing impedance immunosensor for quantification of 
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biomarkers in bodily fluid, its method of manufacture and method of use. The 
specific aims are:  
1.4.1 Specific Aim 1: PCB Biosensors 
 The first specific aim is to test the hypothesis that various cytokines 
induce empirically determinable frequencies of response when captured by a 
PCB impedance immunosensor surface. This was accomplished by determining 
via cyclic voltammetry (CV), and EIS methods the limits of detection, dynamic 
range, and response at all frequencies in the sweep. Other metrics to be 
determined included background interaction.  
1.4.2 Specific Aim 2: Gold Disk Electrode Experiments 
 The second specific aim is to test the hypothesis that rapid detection of 
cytokine analytes via impedance immunosensing can be done without greatly 
sacrificing sensitivity. This was done by determining via CV, EIS and fixed 
frequency impedance over time (Zt) methods the limits of detection, dynamic 
range, detection time and frequency of response of IL-12 on CHI gold disk 
electrodes.  
1.4.3 Specific Aim 3: Prototype Design 
 The third specific aim is the design of a multiplexing impedance 
immunosensor for quantification of biomarkers in multiple types of bodily fluid, its 
method manufacture and method of use. Detailed include methods and devices 
for sample handling, single sensor prototypes, mass production arrays, and data 
analysis methods thereof.  
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1.5 Organization of Dissertation  
 Chapter 1 provides an introduction to the dissertation and discusses the 
hypotheses, specific aims, rationale and significance of the study.  
Chapter 2 is a review of the literature on biomarkers of disease found in 
bodily fluid, multimarker approaches to disease diagnosis, classification and 
variety of biosensors, immobilization methods and the electrochemical 
transduction methods cyclic voltammetry and electrochemical impedance 
spectroscopy.  
Chapter 3 discusses the development and testing of PCB impedance 
biosensors, including empirical determination of the limit of detection, tolerance 
to complex solutions and optimal frequency of detection for multiple biomarkers 
(Specific Aim 1). 
Chapter 4 discusses further experiments on CHI gold disk electrodes 
towards a simultaneous multiplexing system, including minimum detection time 
determination via Zt and confirmation of optimal frequency of detection via EIS 
(Specific Aim 2). 
Chapter 5 discusses a bodily fluid biosensor prototype, including a model 
for array fabrication, a method for sample handling, and methods of data analysis 
(Specific Aim 3). 
Chapter 6 provides a summary of the results and conclusions that can be 
drawn from all the chapters and suggests future avenues that can be explored 
based on the conclusions.  
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Each chapter is self-contained, with an introduction, description of the 
research design and methods, results, and discussion. A bibliography for the 
entire dissertation is presented at the end of the document.  
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CHAPTER 2 
LITERATURE REVIEW: DISEASE BIOMARKERS, BIOSENSORS, AND 
ELECTROCHEMICAL IMPEDANCE SPECTROSCOPY 
2.1 Introduction  
 A biosensor is “a device that uses specific biochemical reactions 
mediated by isolated enzymes, immunosystems, tissues, organelles or whole 
cells to detect chemical compounds usually by electrical, thermal or optical 
signals,” (Nic 2010). In many diseases, early detection and monitoring results in 
better outcomes. Early detection results not just from sensitive diagnostic 
techniques, but also from affordable and convenient methods. Biosensors offer 
not only sensitivity and selectivity, but also convenient and inexpensive means 
for the detection of disease biomarkers. Convenience and low cost render them 
advantageous for regular monitoring of medical conditions. Coal mine canaries, 
by detecting dangerous subterranean gases, would qualify as whole-organism 
biosensors. If limited to purpose-built biosensors however, the first example 
would be an electrocatalytic Glucose-Oxidase (GOD) enzyme-based sensor for 
the detection of glucose, first publicized in 1962 (Clark 1962). This quantified 
glucose in diabetes patients‟ blood samples through electrochemical detection of 
enzyme activity, in this case the reduced presence of oxygen. The sensor was 
amperometric- operated by measuring the current resulting from voltage applied 
to the electric cell- current resulting from oxygen reducing at the cathode. Since 
then, many different biosensor recognition and transduction methods have been 
developed, with different advantages and drawbacks.  
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 Biosensors can be made selective, having high specificity for the desired 
target. Using biomolecules that can often discriminate between very closely 
related analytes, for example antibodies or enzymes, high selectivity in the 
sensors themselves can be achieved. However, there is often a tradeoff between 
selectivity and sensitivity. Reproducibility, stability over time and rapid detection 
are also key attributes of a biosensor. Finally, biosensors can be made to be 
inexpensive, durable, and simple to use. This improves their utility for clinical and 
home use, as best illustrated by commercial glucose sensors. Taking advantage 
of biomolecule specificity, biomarkers of disease are attractive targets for 
biosensor development (Soper et al. 2006).  
2.2 Disease Biomarkers 
 Biomolecules, i.e. biomarkers indicative of disease states, can be found in 
biopsies, blood, serum, urine, sweat, tears, and saliva. Monitoring of biomarkers 
found in bodily fluids is especially attractive because of the relative ease, low 
expense, and convenience of collection. Important components of the immune 
system, circulating cytokine levels are important biomarkers of many disease 
states. 
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Fig. 2.1 Cytokine Biomarkers for Disease States: Yellow- Diagnostic, Blue- Prognostic, Green- Both 
diagnostic as well as prognostic   Abbreviations include: Multiple Sclerosis (MS), Rheumatoid 
Arthritis (RA), Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), Myocardial 
Infarction (MI), Acute Coronary Syndromes (ACS), Interleukin (IL), Interferon gamma (IFN-γ), 
Tumor Necrosis Factor alpha (TNF-α), Monocyte-Induced Gamma Interferon (MIG), Hepatocyte 
Growth Factor (HGF), and C-C Motif Chemokine Ligand 5 (CCL5). See section 2.2 for references. 
 
2.2.1 Multiple sclerosis 
There are a large variety of individual biomolecules with different degrees 
of effectiveness as biomarkers for Multiple Sclerosis (MS), and cytokines are 
among the most effective (Bielekova and Martin 2004; Giovannoni 2006). Serum 
cytokines relevant as MS biomarkers include interleukin (IL) -1β, IL-2, IL-6, IL-10, 
IL-12, interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α) in 
remission stages (Giovannoni et al. 1997; Hollifield et al. 2003; Nicoletti et al. 
1996; Woodroofe et al. 1991).  
For example, the 75kDa cytokine IL-12 is a proinflammatory marker which 
ranges between 0-5 pg/ml in normal serum, while rising to 5.5-18.9 pg/ml during 
MS (Hafler and Weiner 1995; Leonard et al. 1995; Nicoletti et al. 1996). During 
remission step testing, IL-12 levels decrease back to normal levels. Because of 
the cyclic nature of the cytokine pathway in MS, and the fact that other ailments 
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or diseases could interfere with a single marker sensor, a multimarker sensor 
would be of benefit. Studies have shown that changes in cytokine IL-12 level are 
observed in stroke, brain inflammation, Lyme disease infections (Garcia-Monco 
et al. 1990; Hansen et al. 1990; Kohler et al. 1988; Schluesener et al. 1989), 
tumors, and lupus (Steinman 2001). Serum IL-12 is elevated in Secondary 
Progressive MS. Elevated expression of the IL-12p40 subunit is seen in the 
cerebrospinal fluid of relapsing/remitting MS patients with active plaques 
demonstrated by magnetic resonance imaging (Galboiz and Miller 2002). Levels 
of another cytokine, IL-10, have been shown to drop in MS patients and in other 
diseases such as Crohn‟s (Detkova et al. 2003), and also in pregnant women 
(Holmes et al. 2003). 
2.2.2 Cancer 
Serum biomarkers have been tested for efficacy in distinguishing 
malignant thyroid tumors from benign thyroid tumors and undiseased thyroid. IL-
5 was found to be the best univariate thyroid cancer marker. In a multimarker 
panel, Interleukin-8 (IL-8), epithelial growth factor, hepatocyte growth factor 
(HGF) and Interleukin-12 P40 were the most effacious four factors separating 
neoplastic and normal thyroids (Linkov et al. 2008). Multimarker panels have 
been found to be more effacious than their individual constituents for prediction 
and detection of breast cancer metastases (Molina et al. 2005).  
2.2.3 Rhumatoid arthritis (RA) 
Joint biopsies of rodent models of RA showed elevated IL-1B, TNF-α, and 
IL-6. These biomarkers are also found elevated in the synovial fluid of human RA 
patients. Successful prednisolone treatment of the RA rodent models 
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corresponded with a reduction in IL-1B and IL-6 levels (Rioja et al. 2004). IL-6 
and IL-1a are serum biomarkers of response to treatment of RA by etanercept 
(Hueber et al. 2009).  
2.2.4 Irritable Bowel Syndrome (IBS) 
Female IBS patients were found to have elevated serum IL-6 and IL-8, 
tested via an electrochemiluminescent immunoassay, compared to age-matched 
controls. Those patients with extra-intestinal symptoms also had elevated IL-1B 
and TNF-α (Scully et al. 2010).  
2.2.5 Inflammatory Bowel Disease (IBD) 
In a murine model of IBD, serum IL-4, IL-6, IL-12, IL-17 and INF-γ were 
found to best discriminate between healthy and sick animals, and between 
various types of disease (Alex et al. 2009). In serum taken from IBD patients, IL-
1 , IL-4, IL-6 and TNF-α were found to discriminate between different disease 
types (Alex 2008).  
2.2.6 Trauma 
Late-onset multiple organ failure could be predicted among trauma 
patients using a combination of serum IL-6 and sTNF-R levels (Maier et al. 
2007).  
2.2.7 Sepsis 
Septic febrile neutropenic patients were found to have higher levels of 
serum IL-8 compared to nonseptic febrile neutropenic patients (El-Maghraby et 
al. 2007). IL-10 was found to be higher in septic shock patients than cardiogenic 
shock patients (Marchant et al. 1995). Elevated serum IL-12 was found to be 
diagnostic of sepsis in neonatal patients. Serum IL-10 levels were also 
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diagnostic, though at lower sensitivity (Sherwin et al. 2008). Trauma patients with 
sepsis were found to have higher IL-18 than those without (Oberholzer et al. 
2001).  
2.2.8 Lupus  
Serum IL-10 and IL-6 are significantly elevated in Systemic Lupus 
Erythematosus (SLE). Depending on other factors, IL-2 is either depressed or 
elevated among SLE patients (Chun et al. 2007). IL-12 levels have also been 
found to be significantly elevated in SLE patients (Manukyan et al. 2010). 
2.2.9 Acute Coronary syndromes (incl. heart attacks) 
In unstable angina cases, an increase in serum IL-6 levels that occurs 
within 8 hours after admission is associated with increased incidence of 
myocardial infarction (MI), refractory angina and death. High IL-6 levels are 
indicative of angina cases that benefit most from invasive procedures. Among 
recovering patients, elevated TNF-α is associated with recurrent Myocardial 
Infarction (MI) and death. TNF-α in 95th percentile indicated 2.7x risk of death/ 
MI. Mouse experiments show elevated IL-18 are indicative of arterial plaque 
formation (Armstrong et al. 2006), while elevated circulating IL-6, IL-10, IL-18 and 
TNF levels in humans are linked to the existence of arterial plaques (Vasan 
2006).  
2.2.10 Organ rejection 
Serum TNF-alpha has been found to be elevated in liver transplant 
patients with acute transplant rejection (Platz et al. 1996). Circulating IL-6 was 
found to be four times higher in patients with postoperative complications 
compared to patients without. IL-10 plasma concentrations also may serve as a 
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useful biomarker of postoperative complications in liver transplant patients 
(Hassan et al. 2006).  
2.2.11 Multimarker detection for disease state evaluation 
Using multiple factors has been found to be much more effective than 
using one for detecting trisomy 21, in terms of sensitivity, specificity, and cost 
effectiveness (Schneider and Mizejewski 2007), while markers such as serum 
Transforming growth factor (TGF) - 1 and IL-6 add specificity and sensitivity 
when staging prostate tumors (Steuber et al. 2007). Combining information from 
evaluating four prostate cancer markers found in urine exceeded the sensitivity 
and specificity of those markers alone, and far outperforms serum prostate-
specific antigen (PSA) for diagnosis (Laxman et al. 2008).  
Multimarker with empirically selected serum biomarkers exceeded 
sensitivity and specificity of ovarian cancer detection with its signature biomarker, 
CA 125 (Kozak et al. 2003). Analysis of gene expression from ovarian cancer 
biopsies revealed many potential biomarkers. A multimarker approach with 
groups of responsive, covarying markers proved, when compared with groups of 
markers with the best receiving operater characteristic (ROC) curves, ie. more 
sensitive and selective (Tchagang et al. 2008).  
 Cytokeratin-19 (CK-19), mammaglobin-2 (MGB-2) and NY-BR-1 mRNA 
were quantified in sentinel lymph node biopsies of breast cancer patients via 
reverse-transcription polymerase chain reaction (RT-PCR). This three-marker 
method was found to have a superior ROC curve when compared to two-marker 
histochemistry analysis of sentinel lymph nodes biopsies for metastases 
detection (Nissan et al. 2006).  
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Disease states where use of multiple biomarkers is confirmed to improve 
diagnostic sensitivity and selectivity serve to illustrate the advantage of using 
multiple biomarkers for that purpose. By definition, adding factors such as 
biomarkers to a model will increase the predictive value of the model. However, 
these additional factors must be examined to evaluate if they contribute more 
than a theoretical factor which varies randomly in relation to the response 
variable (eg. the disease state) (Montgomery 2005). The variety of cytokine 
biomarkers diagnostic to many disease states would serve as impetus for 
exploration of systems to detect and quantify these biomolecules. One such 
category of systems would be biosensors.  
2.3 Biosensors  
Biosensors detect or quantify analytes using biological material or a 
biomimetic recognition element associated with a transducer to achieve 
detection. Biosensors can be classified by both their recognition element and 
their transducer, device elements held in close physical proximity by an interface 
method. Recognition elements can be enzymatic, immunological, nucleic acid 
based, or based on other selective biological molecules. These physically 
interact with the target. Signal from enzymes consists of the reaction products. 
Transduction methods for enzymatic signaling are usually electrical, optical or 
fluorescent. Signal from most immunological, nucleic acid based, or other affinity 
biomolecule based recognition elements is the close physical association with 
the target. Transduction methods for affinity biosensors, if enzymatic labeling is 
not involved, are usually electrical, optical or piezoelectric (Kissinger 2005; Nicu 
and Leïchlé 2008).  
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Fig. 2.2 Schematic of a Biosensor:  Biosensors consist of a biological or biomimetic recognition 
element held in close physical proximity to a signal transducer. Recognition elements physically 
interact with the target to be detected. These can be any kind of selective biological molecule, but 
usually are enzymatic, immunological, or nucleic acid based. Transducing the biological signal into 
an electrical signal is usually done by electrical, optical, fluorescent, or piezoelectric means 
(Kissinger 2005; Nicu and Leïchlé 2008).  
 
2.3.1 Biosensor Recognition Elements  
 Biosensor recognition elements are usually classified as one of two types- 
affinity biosensors, which physically associate with the target analyte, and 
enzymatic biosensors, which react with the target analyte. Affinity biosensors 
take advantage of the selective binding properties of certain biomolecules, most 
often antibodies, receptors or nucleic acids. Biomolecules with high affinity and 
specificity for the given target are desirable. Most often observed in this category 
are immunosensors, taking advantage of versatile antibody libraries. A target 
analyte is used to produce polyclonal antibodies in a host organism, or to create 
a line of monoclonal antibodies. Antibodies can exhibit cross-reactivity, or 
nonspecific binding, reducing the specificity of the immunosensor and its 
tolerance for complex solutions. If antibodies can be raised against something, 
then an immunosensor can be created for the target- including bacteria, viruses, 
drugs and other chemicals. Applications of immunosensors include food safety, 
environmental monitoring, biowarfare monitoring (Eggins 2002), and disease 
diagnosis (Tang et al. 2007). Less commonly, nucleic acids have been used as 
recognition elements, either as straight strands to detect complementary nucleic 
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acids, or as aptamers, which are biomolecules with tertiary structure selected for 
affinity against a specific target. Nucleic acid sensors for detection of specific 
nucleic acid sequences find application in detection of cancers, viruses and 
alleles. Aptamers find applications more like those of immunosensors 
(Ronkainen et al. 2010). 
Catalytic or biocatalytic or enzymatic biosensors are a major division of 
biosensing devices that use enzyme recognition elements for their specificity and 
their catalytic activity using purified enzymes, whole cells or tissue sections in the 
biosensor. Enzymes have very selective catalytic activity versus a specific target, 
they are usually very tolerant of complex mixtures. Enzymatic biosensors are set 
up to recognize the enzyme product. Enzymatic sensors are less versatile than 
affinity biosensors, relying on a limited library of enzymes (Ronkainen et al. 
2010). The blood glucose monitor, the most commercially successful biosensor, 
employs the enzyme glucose oxidase (Nicu and Leïchlé 2008).  
2.3.2 Biosensor Transducers  
Transducers convert a biological recognition event into an electrical 
signal. Transducers used include optical, electrical (more properly 
electroanalytical), thermal, piezoelectric (Song et al. 2006) and acoustic (Lowe 
2008) means of signal production. Piezoelectric transducers have included 
quartz crystal microbalance (Janshoff et al. 1997; Tedeschi et al. 2005) and 
cantilever (Campbell and Mutharasan 2008). Optical transducers include 
absorbance (Aoyagi and Kudo 2005); chemiluminescence (Mathew and Alocilja 
2005); a hand-held laser induced fluorescence detector (Fruetel et al. 2005); and 
surface plasmon resonance (Leonard et al. 2004; Rasooly 2001). Less 
catagorizable transducers employed include surface acoustic wave devices 
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(Berkenpas et al. 2004) and semiconductor based field effect transistors 
(Schoning and Poghossian 2002). Electrical transducers include potentiometric, 
amperometric, and impedimetric/conductimetric devices (Nicu and Leïchlé 2008; 
Wang 2006), which can be enhanced with magnetic nanoparticles (Fredj et al. 
2008).  
Electrochemical transduction techniques can operate with both affinity 
and enzymatic recognition elements, though not all will be equally optimal. These 
techniques can be organized by the method of measurement, which includes 
current, voltage, or impedance measurement.  
For voltammetric and amperometric techniques, the current of an 
electrochemical circuit is measured. Typically, a voltage is applied to a working 
electrode versus a reference electrode, and current is measured at the working 
electrode. This current comes from electrochemical redox reactions at the 
working electrode surface, limited by mass transport. In amperometric 
techniques, a constant potential is applied and current is measured over time. In 
voltammetric techniques, current is measured in response to alteration of 
potential with time. Amperometric techniques include single-potential 
amperometry and pulsed amperometry (Trojanowicz et al. 2003). Voltammetric 
techniques include linear sweep voltammetry, cyclic voltammetry, hydrodynamic 
voltammetry, differential pulse voltammetry, square-wave voltammetry, ac 
voltammetry, polarography, and stripping voltammetry (Ramirez et al. 2009; 
Ronkainen et al. 2010). The key to using these techniques for biosensor 
transduction is to have an electroactive chemical as the biological measurand or 
as a proxy for the biomarker.  
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Cyclic Voltammetry (CV) is a very commonly used voltammetric 
technique. CV is a useful method for the studying electroactive species and 
electrode surfaces (Demirok 2010). In this electrolytic method, the solution is 
unstirred such that the measured current is limited by target diffusion at the 
working electrode surface. The input voltage is a series of linear sweeps back 
and forth between two voltages. The forward scan produces a current peak for 
oxidation of any analyte through the range of the potential scan. The current 
increases as the oxidation potential of the target is reached, and falls off as the 
target is depleted close to the electrode surface. Following the reverse linear 
voltage sweep, it reaches a potential where product formed during forward scan 
starts reducing and produces a current of reverse polarity from the forward scan. 
This produces a reduction current peak, usually mirroring the oxidation peak in 
shape. Larger differences or nonsymmetric reduction and oxidation peaks can 
indicate a nonreversible reaction. The parameters of CV make the technique 
useful for studies of redox reactions at electrode surfaces.  
The parameters that can be derived from CV include the magnitude of 
peak current (Ip), peak potential (Ep), number of electrons transferred per 
reactant molecule (n), rate constant, diffusion coefficient (D), and electrochemical 
reversibility. In reversible systems, Ip is described by the Randles–Sevcik 
equation.  
Ip = 2.69 × 10
5An3/2D1/2v1/2C  (2.1) 
Where A is electrode area, C is target concentration and v is the scan 
rate (V * s−1) (Bard and Faulkner 2001). In a theoretically reversible system at 
STP, peak separation is 59 mV divided by the number of electrons transferred 
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per reactant molecule (Arya 2008). Cyclic voltammetry can be used to quantify 
the concentration of redox species in solution.  
Current resulting from reversible electrochemical systems controlled by 
charge transfer at the electrode can also be evaluated by the Butler-Volmer 
equation (Eq. 2.2), where i is current density, αc and αa are the charge transfer 
coefficients for the cathode and anode respectively, n is the number of electrons 
involved in the reaction, F is the Faraday constant, R is the universal gas 
constant, and η is the activation overpotential (Ozarem and Tribollet 2008).   
RT
nF
RT
nF
ii cao exp
(
exp  (2.2) 
In potentiomeric methods, the potential of an electrochemical system is 
measured at negligible current. Examples include glass pH electrodes and ion-
selective electrodes. By coating these sensors with an enzyme that produces an 
ion specific to the electrode type, these sensors can be employed as biosensor 
transducers (Ronkainen et al. 2010).  
In impedimetric/conductimetric methods, conductivity is measured at a 
series of frequencies (Arya 2008). Impedance spectroscopy biosensors operate 
by input of a small signal and by comparison with the output signal determining 
the real and imaginary impedance (Bard and Faulkner 2001). The most 
prominent method is Electrochemical Impedance Spectroscopy (EIS). 
Impedance biosensors measure the electrical impedance of an interface 
in AC steady state by imposing a small sinusoidal voltage at a particular 
frequency, with a DC offset, and comparing the resulting current with the input. 
The impedance is given by the resulting current-voltage ratio. When repeated at 
different frequencies, the technique is called EIS. EIS has been used to study 
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electrochemical phenomena, mostly affinity, of many different biological 
interactions (Daniels and Pourmand 2007). If the impedance of the electrode 
solution interface changes when the target analyte is captured by the probe, EIS 
can detect that impedance change. Alternatively, the impedance or capacitance 
of the interface may be measured at a single frequency. Impedance 
measurement can be performed label-free (Daniels and Pourmand 2007; Davis 
et al. 2005; Katz and Willner 2003; Muhammad-Tahir and Alocilja 2003; Tlili 
2006). EIS is a rapid, sensitive technique that has been heavily employed for 
biosensor signal transduction. EIS biosensors detect their target analytes at 
concentrations of pg/ml and lower (La Belle et al. 2007). Unlabeled EIS sensing 
in other laboratories has been shown to detect proteins to a lower limit of 1pg/ml 
concentration (Tsai et al. 2011).  
2.3.3 Biosensor Immobilization Techniques 
 It is also important to get the affinity recognition element in close proximity 
to its transducer. This is done with direct adsorption to a sensor surface, physical 
entrapment in or onto a polymer layer, direct covalent attachment, or by use of a 
linker molecule. The immobilization method used depends on the recognition 
element, the transducer and the stability requirements for the biosensor. There 
are advantages and disadvantages to each technique. A selection of 
immobilization techniques are illustrated in Fig. 2.3.  
Direct adsorption, relying on a hydrophobic surface, is simple, fast and 
inexpensive, but only really optimal for single-use sensors. The immobilization is 
relatively unstable, depending on local pH, temperature, and the nature of the 
adsorped biomolecule itself. Many biomolecules, especially proteins, can 
denature and lose function because of the hydrophobic interaction. If the 
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hydrophobic surface is not blocked most proteins will be able to denature and 
adhere to it, producing a nonspecific signal for many sensor types.  
Entrapment of the recognition element behind a permeable membrane is 
simple and can be done with practically anything. This is one of the only 
approaches for affixing tissue to a sensor. The recognition element is well-
insulated, making the sensor more durable and opening up possibilities for long-
term use. Mass production is difficult with this method, and diffusion across the 
membrane slows response time. Related to entrapment behind a permeable 
membrane is entrapment of the recognition element inside a polymer gel. This 
method is good for mass production, but leaves biomolecules vulnerable to 
denaturation by free radicals in the polymer.  
Covalent bonding of the biomolecule to the transducer surface results in 
intimate, stable association between them. Due to the close coupling, there is 
little barrier to target diffusion, producing a rapid-response device. The chemistry 
for this immobilization can be complex and costly. This method can often reduce 
the activity of the biomolecule by hindering its active sites. It also reduces the 
working lifetime of the biomolecule.  
Utilizing both covalent bonding of recognition elements and a surface 
polymer layer, recognition biomolecules can be covalently bonded to a „polymer‟ 
layer, including molecule monolayers. Advantages of this technique include, 
potentially, a controlled number of immobilization sites, lower steric hinderance of 
biomolecule active sites and increased signal size. It can be a relatively complex 
procedure, and on the output side yield more complicated kinetics and diffusion.  
Capture systems like biotin-streptavidin yield surfaces where specificity 
may be freely switched because that they can easily be regenerated after use. 
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These are usually very expensive and involve complicated derivitisation. The 
multi-layer structure can reduce signal, and the components of the system may 
bind to interferents in complex solution (Mayes 2002). 
 A widely- used method of associating the biological recognition element 
of an affinity biosensor with the transducer is use of a self-assembled monolayer 
(SAM). SAMs are organic assemblies formed by absorbing molecules from 
solution or the gas phase onto the surface of solids or in regular arrays on the 
surface of liquids. Metal or metal oxides tend to adsorb organic materials 
because the interactions between these two components low the free energy of 
the interface of metal or metal oxide and the surrounding environment (Adamson 
1997). The adsorbates organize spontaneously into crystalline structures, which 
can alter interfacial properties and have a significant influence on the stability of 
nanostructures of metals and metal oxides. 
. 
Fig. 2.3 Biosensor Immobilization Methods: Recognition elements maintained in close physical 
proximity with transduction elements through examples of (a) physisorption, (b) covalent bonding, 
(c) entrapment, (d) capture systems, (e) phospholipid insertion and (f) self-assembled monolayers. 
 
Two distinct approaches can be used to fabricate SAMs. The Langmuir-
Blodgett technique involves the transfer of a pre-assembled film at an air-water 
interface to a solid substrate, whereas the spontaneous adsorption of molecules 
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onto a substrate by immersing the substrate into an appropriate amphiphile 
(Ulman 1996). 
Although there are a large number of molecules able to form SAMs on a 
solid substrate, the organosulfur (alkylthiols, di-n-alkyl disulfides etc.) /noble 
metal system is the most investigated to date. It is the best characterized system 
in terms of stability and physico-chemical properties. The mechanism of 
chemisorption of alkylthiols on gold is considered to be an oxidative addition of S-
H bond followed by reductive elimination of hydrogen (Eq. 2.3). 
R-S-H+Au0n___________R-S-Au
+•Au0n+1/2H2 (2.3) 
R-S-S-R+Au0n________2R-S- Au
+•Au0n+H2 (2.4) 
In the case of disulfides, the mechanism is thought to follow Eq. 3 (Ulman 
1996). The alkyl chains of thiols are in the all trans-conformation, tilted at an 
angle of ~20-30o from normal to gold surface (Bain et al. 1989).   
SAMs are easy to prepare, and no special instruments or harsh 
conditions are required to construct such a system. They are critical in stabilizing 
and functionalizing nanomaterials, and can link the external environment to the 
properties of substrates (e.g. electric and optical properties of metallic structures) 
(Phoenix and Drexler 2004). It is simple to link biomolecules to electrode 
surfaces using SAMs (see Chapter 3, Fig. 3.4). The incorporation of multiple 
molecular components within a monolayer offers the opportunity to control the 
microenvironment at molecular level and makes such system even more 
versatile. All these features make SAMs play an important role in biosensing, 
drug delivery and molecular imagine and many other fields. 
The well organized molecular architecture on the sensing surface is 
resistant to specific adsorption of undesired entities and is able to bind selected 
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biological species (i.e. proteins, nucleic acids and whole cells). For this particular 
purpose, mixed alkylthiol SAMs can be prepared by coadsorption of alkylthiols 
with different length and functional end groups on the substrates. One thiol 
molecule carries a functional group (e.g. – carboxyl) that can be used to 
covalently bind biological reporters and the other thiol molecule has a functional 
group (e.g. –hydroxyl) that shows resistance to nonspecific adsorption (Uchida et 
al. 2005). 
2.4 Electrochemical Impedance Spectroscopy (EIS)  
 EIS was introduced in chapter 2, section 2.3 (transducers). In order to 
model a system using the technique, a frequency sweep is taken over a 
frequency range (for instance, 1Hz-100,000Hz) under appropriate run conditions, 
Vapplied, amplitude, redox probe concentration, etc. Electronic impedance 
measurements of total impedance (Z), the real component of impedance (Z‟), 
and the imaginary component of impedance (Z”) are done at each frequency. A 
Nyquist plot will be made using the values for the real component (Z‟) on the x-
axis and the values for the imaginary component (Z”) on the y-axis. This process 
is illustrated in Fig. 2.4.  
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 Fig. 2.4 Electrochemical Impedance Spectroscopy (EIS) Data and Analysis: (a) Initial processing 
of EIS data requires comparing (input) a sinusoidal voltage which is applied to the sensor and the 
(output) resultant current reconverted to voltage to determine the (θ) phase shift and ([Z]) absolute 
impedance of the system, the latter of which is proportional to the reduction in amplitude. The 
resulting information can be used in (b) Bode plots, which can compare the absolute impedance or 
the phase shift versus frequency, or in (c) Nyquist plots, which compare (Z‟) real, and (Z”) 
imaginary components of the resulting impedance, which may both be determined from the phase 
shift and the absolute impedance.  
 
After electrical data has been received, it must be interpreted 
appropriately. The most general form of modeling of the data from EIS comes 
from an equivalent circuit model approach using a Warburg coefficient. Other 
complex models for EIS have also been developed. In many impedance 
spectroscopy biosensors, models besides Randles or Warburg are used to fit the 
data (Lasseter et al. 2004; Navratilova and Skladal 2004; Peng et al. 2007; 
Rickert et al. 1996). Constant phase elements are often used to interpret data 
that otherwise would be cumbersome using only standard circuit elements 
(McMillion et al. 2005). These basic circuits for Nyquist modeling along with their 
associated plots are shown in Fig. 2.5. 
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Fig. 2.5 Nyquist EIS Nyquist Plots and Equivalent Circuit Models: Data plots corresponding with 
equivalent circuit models of impedance, including (a) Randles, incorporating Rs, representing 
solution resistance, Cdl, representing the double-layer capacitance of the electrode surface, and 
Ret, representing the Resistance of the electrode surface, (b) Warburg, additionally incorporating 
(W) a warburg element representing diffusion-limited transfer of electrons and (c) Constant Phase 
Element models, incorporating a constant phase element indicative of an uneven or rough 
electrode surface.  
 
The general form of a Nyquist plot for these experiments will be a partial 
semicircle followed by a linear region as is seen in Fig. 2.5b. If a very fast 
electron transfer process occurs, the radius semicircle will be very small, and the 
curve will primarily consist of the linear region. If a very slow electron transfer 
process occurs, the semicircle region will be present with no linear area (Fig. 
2.5a). The Nyquist plot can be plotted using the Z‟ and Z” values in ZsimpWin™, 
Microsoft Excel™ or an equivalent program. Once the Nyquist plot has been 
created, a 2nd order polynomial equation can be fit to the values in the semicircle 
region of the curve. Using this equation the maximum value of the plot, as well as 
each of the two intercepts with the real impedance axis (x-axis), is calculated. 
The solution resistance (Rs) and Warburg Impedance (Zw) are properties of the 
bulk electrolyte solution and diffusion properties of the redox probe. The solution 
resistance can be calculated as the intercept of the semicircle (for instance as 
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seen in Fig. 2.4 and Fig. 2.5a) with the Z‟ axis in the high frequency (low Z‟ value) 
ranges (Katz and Willner 2003).  
The electron transfer resistance (Ret) controls the electron transfer 
kinetics of the redox probe at the electrode interface. The immobilized IgG and 
bound IL-12 will serve as a varying electron transfer resistance (Rimm and Rbound) 
connected in series with the constant electron resistance of the unmodified 
electrode (Relec) resulting in Eq. 2.5: 
Ret = Relec + Rimm + Rbound             (2.5) 
 The electron transfer resistance is a function of the heterogeneous 
electron transfer rate constant (ket). This is shown in Eq. 5 below, where R= 8.31 
J mol-1 K-1 (gas constant), T is the temperature (K), F=9.65 x 104 C equiv-1 
(Faraday constant), A is electrode area (cm2), [S] is the concentration of redox 
probe (mol cm-3), and n is the number of molecules transferred per molecule of 
redox probe (Katz and Willner 2003). 
    (2.6) 
The value for electron transfer resistance can be easily calculated using 
the Nyquist plot. The difference between the two values of the semicircle 
intercept with the Z‟ axis is equal to the electron transfer resistance.  
The double layer capacitance depends on the electrical double layer, and 
is a function of the dielectric permittivity introduced into the double charged layer 
molecules (Cdl). The equation below can be used to determine the capacitance. 
In this equation A is the area of the electrode (cm2), δ is the thickness of the 
separating layer, εo is the dielectric constant of a vacuum, and εp is the dielectric 
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constant of the separating layer (Katz and Willner 2003), as can be seen in Eq. 
2.7.  
 (2.7) 
 Just as the electron transfer resistance can be calculated as resistors in 
series, the double layer can be calculated as capacitors in series. The result is 
that the double layer capacitance is controlled by the smallest capacitance, as 
shown in Eq. 2.8.  
Cdl
-1 = Celec
-1
 + Cimm
-1
 + Cbound
-1                                 (2.8) 
In order to calculate the double layer capacitance, the characteristic 
frequency of the system must be found. The characteristic frequency (fo) is 
calculated by determining the frequency in Hz (as measured during the EIS 
testing) that corresponds to the maximum value on the polynomial curve. This 
frequency is multiplied by 2π to convert it to units of radians/second, and is equal 
to ωo (Katz and Willner 2003): 
ωo =2πfo (2.9) 
This characteristic frequency is computed as in Eq. 2.10. 
fo=(Cdl Ret)
-1                       (2.10) 
 The double layer capacitance can be calculated using the characteristic 
frequency and the electron transfer resistance, and thus from the Nyquist plot, 
and is calculated as seen in Eq. 2.11.  
Cdl = (foRet)
-1                    (2.11) 
 Both Cdl and Ret are important parameters for evaluation of an 
electrochemical system, and for these studies, evaluation of a biosensor surface, 
though other parameters of interest were determined, most importantly the 
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optimal frequency of detection and the impedance at the optimal frequency of 
detection (see chapters 3 and 4). Briefly, the raw data and plots of frequency 
versus impedance at different target concentrations were used to determine the 
frequency of maximum response over the concentration range tested. The 
impedances determined at this optimal frequency were plotted versus target 
concentration to obtain a relationship with target concentration.  
2.5 Conclusions 
The remainder of this dissertation provides the experimental protocol, results, 
analysis, and proposals for future work to be done. Chapter 3 discusses the 
development and testing of printed circuit board EIS biosensors, including the 
determination of optimal frequency of detection for individual biomarkers. 
Chapter 4 discusses studies performed on commercial gold electrodes, including 
fixed frequency experiments towards making use of the optimal frequency of 
detection and determining minimum detection time. Chapter 5 discusses the 
design of and protocol of use for a bodily fluid biosensor prototype utilizing 
multiple fixed frequencies for simultaneous quantification of multiple analytes on 
one sensor. Chapter 6 provides a summary of results and conclusions, and 
suggestions for future work based on these studies. 
. 
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CHAPTER 3 
PRINTED CIRCUIT BOARD IMPEDANCE BIOSENSORS: DETERMINATION 
OF OPTIMAL DETECTION FREQUENCIES 
3.1 Introduction 
 Chapter 2 discussed disease biomarkers and methods of biosensing, 
including Electrochemical Impedance Spectroscopy (EIS). An immunosensor 
utilizing unlabeled EIS makes sense as a technology with the goal of creating a 
sensitive, inexpensive, rapid biosensor to fill the gap between primary disease 
screening and intensive laboratory testing. Development requires the creation of 
an initial prototype system, as detailed in this chapter. Criteria for assessing the 
system should be obtained, and extant unlabeled EIS state of the art forms a 
benchmark for evaluation of the system. The system must be physically created, 
so the electrode must be built from something, and a method of immobilization 
and a target molecule and corresponding affinity molecule must be chosen. 
Printed circuit boards (PCB) form an excellent basis for flexible, rapid 
construction of electrodes. As well, IL-12 is a biomarker with low physiological 
and disease-state concentrations, requiring sensitivity in detection systems, thus 
making a good choice for a test molecule for detection in the development of an 
ostensibly sensitive system.  
3.1.1 EIS Biosensors 
 Unlabeled biosensing with EIS has a significant record in literature, some 
of which is summarized in Fig. 3.1. It has been shown to detect salmonella from 
100 -106 colony-forming-units/ml (CFU/ml), with an incubation time ranging from 
36 
 
2-16 hours (Yang et al. 2004; Yang et al. 2003). Unlabeled EIS immunosensors 
have detected hemoglobin at 20ng/ml (Hleli 2006), 2,4-dichlorophenoxyacetic 
acid at 45nM (10ng/ml) (Navratilova and Skladal 2004), and dust mite antigen 
Der p2 at 1pg/ml (Tsai et al. 2011). Unlabeled EIS immunosensors have 
obtained lower limits of detection of 300pg/ml for 4,4-bis(4-hydroxyphenyl) valeric 
acid (Rahman et al. 2007). Using EIS, antibodies at 0.167mg/ml were detected 
using secondary antibodies in an unlabeled fashion (He et al. 2005). In other 
studies, EIS in conjunction with secondary antibody recognition elements 
detected antibodies with a limit of detection (LOD) of 67 μg /ml, unlabeled (Yang 
et al. 2007). Synthetic peptide recognition elements, used with EIS, have 
detected antibodies at 8.7μg/ml (Rickert et al. 1996). Synthetic peptide EIS-
systems have also been used for detection of biomarkers (CDK2) at a limit of 
50pM, or 1.7ng/ml (Evans et al. 2008). Aptamers have been used as recognition 
elements for EIS sensors to detect proteins at 100nM with platelet-derived 
growth factor (PDGF) (Degefa and Kwak 2008), 10pM (360pg/ml) thrombin and 
10nM (5ng/ml) ATP (Du et al. 2008) and 10pM (170pg/ml) IFN-γ (Min et al. 
2008), while oligonucleotides have been used as EIS recognition elements for 
the detection of nucleic acids (Cai et al. 2004; Davis et al. 2005; Lucarelli et al. 
2005; Patolsky et al. 2001).  
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Fig. 3.1 Unlabeled Detection Limits for Various Targets: Targets (x-axis labels), detected with EIS 
biosensors using recognition elements like secondary antibodies (a, b) (He et al. 2005) (Yang et al. 
2007), synthetic peptides (c, d) (Rickert et al. 1996) (Evans et al. 2008), aptamers (e-g) (Degefa 
and Kwak 2008) (Du et al. 2008) (Min et al. 2008), and antibodies (h-j) (Tsai et al. 2011) (Hleli 
2006) (Rahman et al. 2007). Full target name for (j) is 4,4-bis(4-hydroxyphenyl) valeric acid.  
 
3.1.2 Interleukin-12 
 Not included in the above survey of unlabeled EIS biosensing is previous 
work done in the LaBelle lab detecting Interleukin-12 (IL-12) concentrations using 
gold sputtered silver wire working electrodes down to 5pg/ml (La Belle et al. 
2007). A number of factors influenced choosing IL-12 as a test biomarker for 
impedance immunosensor development. IL-12 is a cytokine biomarker with 
clinically relevant levels in very low ranges. At a molecular weight of 75 kDa, IL-
12 is a heterodimer composed of disulfide-bonded 40 kDa and 35 kDa subunits, 
which themselves have little intrinsic biological activity (Engel and Neurath 2010). 
It is part of a larger family of cytokines that also comprises IL-23 and IL-27 
(Trinchieri 2003). IL-12 is produced by antigen presenting cells including 
macrophages and dendritic cells, and induces protective immunity through its 
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effects on other cytokines and lymphocytes. It is a growth factor for T cells and 
NK cells (Gately et al. 1998), activates Th1 cells, induces cytolytic activity in T 
cells, NK cells, and macrophages, and induces production of other cytokines 
(Metzger 2010). The IL-12 receptor is expressed on T cells and NK cells. Binding 
of IL-12 to its receptor can lead to activation of the STAT4 intracellular pathway, 
though multiple different STAT pathways can be activated (Engel and Neurath 
2010). STAT4 itself is a transcription factor promoting production of proteins that 
affect the cytokine activity of the cell (Wurster et al. 2000).  
 IL-12 is normally found at less than 5.0 pg/ml in healthy adults (Nicoletti et 
al. 1996). It is found at 5.5-19 pg/ml in the serum of MS patients (Hafler and 
Weiner 1995). It is found at elevated serum levels in mice with toxic shock 
syndrome (Gately et al. 1998), children with acute invasive streptococcus 
infections (Wang et al. 2008), patients with thyroid metastases (Linkov et al. 
2008), Systemic Lupus Erythematosus (SLE) (Manukyan et al. 2010) and 
Irritable Bowel Disease (IBD) (Alex et al. 2009). Compared to other bodily fluid 
biomarkers, the healthy (approximately 5pg/ml) and disease state concentrations 
of IL-12 are very low, requiring a very discriminating technique for useful 
quantification and making IL-12 an excellent choice for development of a 
sensitive label-free EIS immunosensor.  
3.1.3 Printed Circuit Board Biosensors 
 With those performance targets in mind for IL-12 detection and unlabeled 
EIS in general, the physical substrate from which the biosensor is constructed 
becomes a present and pertinent choice. In-lab experience, particularly, indicated 
the importance of precise and reproducible positioning of electrodes when 
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performing EIS. The types of biosensor recognition elements and transduction 
methods were discussed in Chapter 2, but the further advantages offered by 
various physical substrates for the transduction element present a subsequent 
choice.  
 Producing the first Printed Circuit Board (PCB), photolithography was first 
applied to pattern conductors on an insulator in 1936 by Paul Eisler (Strong and 
Eisler 1944). In biosensors, printed circuit boards offer the advantages of fast, 
inexpensive, precise and reproducible fabrication. Printed circuit boards are used 
in biosensors as the base of the biosensing device assembly (Beach et al. 2005; 
Dempsey et al. 1997; Jobst et al. 1997; Petrou et al. 2002). More recently, they 
have been employed as the base of the sensing surface itself. Copper is easily 
reactive, potentially leading to noise in an electrochemical assay. Consequently, 
electrochemical biosensors directly incorporating printed circuit boards have 
involved the deposition of material onto the electrode surface, such as carbon 
nanotubes (Yun et al. 2008) or gold (Bhavsar et al. 2009; Fairchild et al. 2009).  
3.2 Methods 
3.2.1 Fabrication of PCB sensor arrays 
 In the current study, the PCB electrodes were a standard three-electrode 
pattern designed to interface with a potentiostat, including an Ag/AgCl reference 
electrode, a gold counter and a gold working electrode. The arrays were 
designed using computer aided design software (AutoCAD, Autodesk) allowing 
for easy modification, and grouped into eight arrays of five electrodes. For 
production, this layout was printed onto a transparency and carefully aligned to 
one, 15.2cm x 15.2cm, pre-sensitized copper clad PCB board (MG Chemicals). 
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The transparency and the board were held in place in a UV light box, where 
unmasked portions of the board were exposed to 423nm UV light for 110 
seconds. The PCB board was removed and promptly immersed in 0.25M, pH 14 
sodium hydroxide (MG Chemicals), for approximately 2 minutes with mild 
agitation and brushing to remove the photoresist. After a thorough rinse with 
distilled water, the board was suspended in a tank with 1.1M ammonium 
persulfate at pH 1 (MG Chemicals) at 40ºC and agitated with air bubbled 
throughout until all exposed copper was removed (8-10 minutes), and then rinsed 
thoroughly with distilled water. The board was then cut into arrays of 5 sensors 
each and stored. This fabrication procedure is summarized in Fig. 3.2.  
 
Fig. 3.2 Photoetching and Development of the PCB Array: First, mask aligned with photoresist-
coated copper-clad board placed into light box (a), to be removed after 2 minutes of UV exposure 
(b). Exposed photoresist removed by immersion and scrubbing with sodium hydroxide developer 
solution (c) followed by rinsing with water to neutralize (d). Developed board etched in ammonium 
persulfate until all exposed copper is removed (e) and then washed with water again to stop 
etchant (f). 
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3.2.2 Electroplating   
 In the electroplating process, a stored array was first rinsed with acetone 
to remove the photoresist, then immersed in sodium perborate (Caswell) at 98ºC 
for 2.5 minutes and slight agitation for degreasing, followed by a distilled water 
rinse and stored in hot distilled water. Allowing only the leads to dry, the array 
was inserted into an edge connector attached to a power supply. The array was 
immersed in nickel sulfate solution (Caswell) pH 4.5 at 43.3ºC, along with a 
nickel anode at a distance of 7cm from the array, and a 10mA/cm2 current 
applied until a total charge transfer of approximately 6.3ºC. The array was rinsed 
with hot distilled water, then degreaser, then with hot distilled water again, 
without removal from the edge connector. The array was then immersed in a gold 
sulfate (Caswell) solution at pH 9.6 and 60ºC, opposite a gold anode 7cm distant. 
0.8mA/cm2 was applied until a total charge transfer of approximately 0.15C. 
Silver nitrate solution was used to brush plate silver onto each reference 
electrode using a fixed potential of 1.7V for 30 seconds. Each silver reference 
was chlorinated with a bleach solution for 2 minutes. 100μl+ volume wells were 
affixed to the array, one well per 3-electrode set. To reduce surface 
contamination, the array was stored in pH 7.4, 1x phosphate buffer saline (PBS) 
at room temperature until use. Fig. 3.3 shows a representative schema of an 
electroplating cell and a set of electroplated sensors.  
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Fig. 3.3 Electroplating: A representative schema of the nickel electroplating cell with the PCB 
electrodes acting as cathode, accepting Nickel ions, while a Nickel anode donates ions to solution 
(left), and a set of freshly gold-plated PCB electrodes attached to a edge connector (right).  
 
3.2.3 Immobilization of antibody 
 The electrodes were immersed in reagent grade ethanol with 1 mM 16-
mercaptohexadecanoic acid (16-MHDA) (Aldrich) in solution, and allowed to set 
at room temperature for 1h. Next, the sensor surfaces were carefully rinsed with 
ethanol and then distilled water. A rubber sheet with well holes (Intl Equip 
Components) was adhered to the board to create wells on the sensor surface 
capable of holding a sample volume of 100μl. A 100μl droplet of a 10mM N-
hydroxysulfosuccinimide (sulfo-NHS) (VWR International), 40 mM N-(3-
dimethylaminopropyl)-N'-ethylcarbodiimide (EDC) (Pierce biotechnology) solution 
was placed in each well, and allowed to sit for 1h at room temperature. After 
rinsing with PBS buffer, a 100 μl droplet of a 50 μg/ml solution of anti-cytokine 
IgG (R&D systems) in PBS buffer was placed in each well and left at room 
temperature for 1h. After rinsing with PBS, 100 μl droplets of 1% ethanolamine 
were added to the wells for 30 min at room temperature to block unreacted 
carboxyl groups of 16-MHDA and EDC/NHS. The blocked sensors were rinsed 
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and stored in PBS at 4 ºC until use. Fig. 3.4 is a summary of steps for 
immobilization of antibody after MHDA deposition.  
 
Fig. 3.4: EDC/NHS Chemistry for Functionalization of the Electrode: Addition of N-(3-
dimethylaminopropyl)-N-ethylcarbodiimide (EDC) to electrode-immobilized 16-
mercaptohexadecanoic acid (MHDA) (a), and the subsequent reaction with N-
hydroxysulfosuccinimide (sulfo-NHS) (b). Addition of antibody (c) and immobilized antibody upon 
substitution for the leaving group (d).  
 
3.2.4 Methods for Verification of Electrode Functionalization 
 To ensure that the antibodies were immobilized onto gold working 
electrode surface, a secondary labeled antibody was used. A 2 μl drop of the 2.5 
μg/ml of an Alexa680 infrared dye labeled secondary antibody was placed in the 
wells of the anti-IL-12 antibody functionalized electrode for one hour at room 
temperature and without any light exposure. Next, the electrodes were washed 
with PBS and immediately imaged using a LI-COR Odyssey Imaging System.  
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 An IL-12 ELISA kit was utilized to test antibody specificity (R&D 
Systems). Dilution sets of recombinant human IL-12, Interleukin-2 (IL-2), 
Interleukin-10 (IL-10), Tumor Necrosis Factor alpha (TNF-α), and Interferon 
gamma (IFN-γ) (R&D Systems) were made. The manufacturer protocol was 
followed in detecting the IL-12 (and cross-reactivity verification studies). In 
summary, 200 μl of sample or control was added to each well, incubated for 2 hrs 
at room temperature then washed. Each well was then incubated for 2 hrs at 
room temperature with μl horseradish peroxidase-labeled anti-IL-12, then 
washed, then incubated for 20 min in the dark with 200 μl of hydrogen peroxide 
and tetramethylbenzidine. Finally, 50 μl of a 2 N sulfuric acid was added to each 
well without washing. A spectrophotometer (UV2501-Shimazdu) was used to test 
the absorbances at 450 nm. A background absorbance at 540 nm was 
subtracted to account for interference from the well material. The other targets 
were detected by similar protocol, the only difference being the substitution of the 
each target for IL-12.  
3.2.5 Electrochemical Methods (CHI 660c) 
 All electrochemical methods were performed with a CHI 660C 
potentiostat (CH Instruments) in series with a CHI 684 64-channel multiplexer 
(CH Instruments). 3-electrode sensor surfaces were immersed in a redox probe 
solution containing 5mM potassium ferrocyanide and 5mM potassium 
ferricyanide in PBS. To employ a sensor array, it was removed from PBS, dried, 
connected to an edge connector in electrical contact with instrument leads, and 
the wells filled with 100μl of redox probe with appropriate concentration of 
antigen or other biomolecules when required. After measurement was done, it 
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could be put into the next stage of immobilization, exposed to appropriate 
experimental conditions, or simply immersed in PBS again.  
 For cyclic voltammetry (CV) measurements, potential started at -0.1V, 
was swept to 0.4 V at the rate of 0.1V per second, then back down to -0.1V. This 
was repeated for a total of 3 cycles. CV was employed to determine the formal 
potential, which was obtained from the average of the cathodic and anodic 
voltage peaks, and also peak separation, which was obtained from the 
comparison of the cathodic and anodic voltage peaks. Peak separation was used 
as a crude measure of surface cleanliness of the sensor or of adsorption to the 
sensor surface.  
 For EIS measurements of the bare electrode, the AC amplitude was set 
to 5mV and swept from 100khz to 1hz, with the static DC offset for the EIS of 
each individual electrode obtained from the bare electrode formal potential as 
shown by CV. The same was done for EIS measurement of the electrode at 
various stages of immobilization.  
 To measure impedance from antigen-sensor interactions the same EIS 
instrument settings were used as described above. Test solutions were also 
prepared using the same redox probe as described above. All cytokine sample 
solutions were diluted in the redox probe and stored at 4 ºC until use. Each 
electrode of the connected PCB electrode array was tested versus each target 
concentration in turn, with no incubation time.  
 To measure sensor-antigen interaction with background interference, 
PCB electrodes were studied with an array of target concentrations in 0%, 1%, 
and 100% fetal bovine serum.  
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3.2.6 Analytical Methods 
 EIS data was analyzed in order to determine equivalent circuit 
parameters and the optimal frequency. In order to evaluate the equivalent circuit 
parameters of the sensors, the Nyquist plots were modeled using software 
(ZSimpWin, Electrochemical software). Circuit parameter fittings via least 
squares iteration were made until an optimal model was determined. EIS circuits 
including but not limited to Randles and Warburg were tested and compared. 
Once the optimal fit was achieved, parameters were tabulated and coefficient of 
determination was calculated over the target concentration range.  
 The raw data and plots of frequency versus impedance at different target 
concentrations were used to develop the frequency of maximum response for 
data interpretation. In order to determine the frequency at which maximum 
changes in impedance are observed, a plot was made of percent change in 
impedance over all the cytokine concentrations tested versus frequency. This 
was also compared to a plot of frequency versus the coefficient of determination 
as determined from linear fits of impedance versus concentration at every 
employed frequency. Thus, an optimal frequency was identified for detection of 
antibody-antigen binding events.  
3.4.2 Determination of Limit of Detection 
 According to the IUPAC Gold Book, the lower Limit of Detection (LOD) is 
the quantity or concentration cL that corresponds with the smallest measure xL, 
that can be detected with reasonable certainty to be different from a blank in a 
given analytical procedure. xL is determined by: 
    (3.1) 
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where x bi is the mean of the blank measures, sbi is the standard deviation of the 
blank measures. The numerical confidence level, k, is usually best chosen to be 
3 (Long and Winefordner 1983; McNaught and Wilkinson 2006). In this particular 
case, repeated blanks were run on separate disposable sensors as to avoid the 
possibility of degradation. The relative standard deviations (RSD) of these blank 
runs were averaged, then the average RSD multiplied by the blank run 
impedance of the sensors which were run versus target (also standing in for x bi) 
to obtain sbi. The relationship between concentration and impedance obtained 
from a regression of the concentration curve was used to calculate cL from the 
resulting xL, as per the IUPAC recommendation. Independent sensors could be 
used in this way to obtain the relative variability of blank runs.  
3.3 Results  
3.3.1 Impedance and Antibody Immobilization 
 Fig. 3.5 shows Nyquist plots taken from the AC sweeps of the bare, 
antibody immobilized (Fig. 3.5b) and biomarker (IL-12) bound electrodes (Fig. 
3.5c, Fig. 3.6c). Fig. 3.6 shows AC sweep experiments on one electrode. Fig. 3.7 
shows Bode plots comparing data from PCB electrodes that, when exposed to 
1000pg/ml IL-12, were interrogated with the EIS transduction technique (Fig. 
3.6c), to an equivalent circuit model incorporating constant phase elements 
(CPE) (Fig. 3.7a insert). Fig. 3.8 shows the slopes of impedance vs 
log(concentration) at each frequency as well as the RSQ values of those slopes 
from the same experiment. Fig. 3.9 shows a plot of concentration versus 
impedance at 5Hz as taken from the AC sweep experiments. Bare electrodes 
(Fig. 3.5a, Fig. 3.6a) displayed a Nyquist plot dominated by the Warburg 
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element. After MHDA was immobilized (Fig. 3.6b), impedance increased to its 
highest point in the experiments, with Nyquist plots relatively dominated by CPE 
double-layer capacitance and the resistance of the electrode. After antibody was 
immobilized (Fig. 3.5b, Fig. 3.6c), the Nyquist plots displayed a decrease, or 
downward shift, with absolute impedance decreasing as well as Ret in some 
models (data not shown). As the target molecules bound to the immobilized 
antibody in a concentration gradient, impedance (and Ret) changed in an 
increasing direction (Fig 3.6c,d, Fig. 3.9). In addition, as the concentration 
gradient proceeded, the CPE elements became proportionally more resistive 
(data not shown). Models incorporating CPEs were the best fit lower-order 
models for data taken after immobilization. As shown (Fig. 3.7), at lower 
frequencies, impedance was dominated by the constant phase element 
resembling a resistor with minor capacitive effects (CPE 2), in series with a 
relatively weak resistor (Ret) (Fig. 3.7 bar scales). Mid-range frequencies were 
dominated by a CPE element (CPE 1) resembling an imperfect capacitor. High-
end frequencies were again dominated by Rs.  
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Fig. 3.5 Immobilization and Modeling of the PCB Electrode: (a) Bare electrode conforming to 
Warburg model (displayed on insert). (b) Anti-IL-12 immobilized electrode and (c) IL-12 detecting 
electrode both conforming to an equivalent circuit model with constant phase elements (displayed 
on insert).  
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Fig. 3.6 Nyquist Spectra on one PCB Electrode: (a) bare, clean electrode (Fig. 3.5a) (b) antibody-
immobilized electrode versus various IL-12 concentrations (including Fig. 3.5b, c) and (c) MHDA-
only on the electrode surface. Insert (d) shows 5 Hz impedance vs log (concentration) for the 
sensor. 
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Fig. 3.7 Equivalent Circuit Modeling: Bode plots comparing EIS PCB immunosensing data (points) 
at 1000pg/ml IL-12 exposure (Fig. 3.6c) against an equivalent circuit model (line). (a) Frequency 
versus Absolute Impedance (|Z|), the dotted lines representing the values of the equivalent circuit 
elements. Insert in (a) is the equivalent circuit model, with a constant phase element (CPE 2) in 
series with a resistor (Ret), both of which are in turn parallel with a constant phase element CPE 1). 
This is in series with another resistor (Ret). The bar scales at the top of (a) and (b) identify the 
circuit elements that dominate |Z| in each frequency range.  
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3.3.2 IL-12 Detection 
 Electrodes were tested against a concentration gradient of IL-12 from 0 to 
1000pg/ml, and the results plotted, as seen in Fig. 3.6c. Increasing the target 
concentration resulted in an increasing absolute impedance at most frequencies 
(Fig. 3.8). Equivalent circuit elements (data not shown) from best fit models also 
displayed significant trends over the concentration gradient.  
 
 
Fig. 3.8 Optimal Frequency Determination: At each individual frequency, taken from the data shown 
in Fig. 3.6c, the slopes of impedance vs log(concentration) (a), as well as the RSQ value of those 
slopes(b). Below 10,000 Hz, the RSQ values of the log/linear fits were above 95%. The greatest 
slope of impedance vs log(concentration) occurred at 1.18Hz. The peak at 4.54 Hz corresponds to 
the typically resulting optimal frequency for IL-12.  
 
 Optimal frequencies were determined by first finding the slope of a fit of 
impedance versus concentration, over the entire concentration gradient, for every 
frequency tested. This result, along with corresponding R2 values, was plotted 
against frequency (Fig. 3.8) to observe patterns in frequency versus response. 
For this experiment, the greatest slope of impedance vs log(concentration) 
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occurred at 1.18Hz. There was also a local maximum at 4.54 Hz with a nearly 
equivalent slope.  
 Impedance at 5Hz (4.54 Hz) was plotted against log[IL-12] (Fig. 3.9) and 
a best-fit model was obtained. This indicated a log-linear relationship between 
the initial test concentration of IL-12 and the impedance resulting from EIS 
interrogation of the exposed immunosensor.  
 
 
Fig. 3.9 Impedances (datapoints) at 5Hz (4.54Hz): for the concentration gradient previously shown 
(Fig. 3.6c). From the linear regression (line), impedance was found to equal 
28.316*ln(concentration) + 1420.8 (ohms).  
 
 In this set (3 sensors, 5 blank experiments per sensor), the average blank 
RSD was found to be 2.72%, or a blank standard deviation of 36.7Ω for this 
sensor. From the commonly followed IUPAC guidelines (Long and Winefordner 
1983; McNaught and Wilkinson 2006), the smallest measure which can 
reasonably be considered distinguishable from no concentration at all would be 
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at 3 standard deviations above the blank measure, or in this case 1462.2Ω. From 
linear regression, the concentration corresponding to the Limit of Detection 
(LOD) in pg/ml is found to be:  
3.28
8.1420x
eC  (3.2) 
where x is the impedance(Ω), resulting in a LOD of 4.3pg/ml. 
 
3.3.3 Multimarker detection 
 PCB sensors were immobilized with various antibodies, and then tested 
against concentration gradients their respective cytokines, IL-2, IL-10, IL-12, IFN-
λ and TNF-α, with the EIS transduction technique. As initial solution 
concentration of antigen increased, resultant Nyquist plots shifted towards an 
increase in impedance. Generally, a log-linear relationship was obtained between 
concentration and impedance, whether from equivalent circuit elements (not 
shown) or from optimal frequency data. The frequency where occurred maximal 
response (optimal frequency), assumed to be the greatest slope of impedance 
change over concentration change, was found for each marker (Fig. 3.10f). For 
each marker at physiological levels, optimal frequency impedances were found to 
be statistically significant over control. For IL-12, optimal frequency was 
confirmed at 5Hz. For IL-2, IL-10, IFN-λ and TNF-α, optimal frequency was found 
at 31.5Hz, 117.2Hz, 17.44Hz and 9.77Hz.  
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Fig. 3.10 Sensor Impedances over Concentration Range of 1 to 10,000 pg/ml: Impedance for each 
MS biomarker on its respective sensor over a wide range of concentration was determined for (a) 
IL-2, (b) IL-10, (c) IL-12, (d) TNF-α, and (e) IFN-γ at optimal frequencies (f). Data adapted from 
(Fairchild et al. 2009). Not shown is the optimal frequency found for IFN-γ, 9.77 Hz.  
 
3.3.4. Background interaction 
 EIS was used to interrogate PCB electrodes exposed to concentration 
gradients of IL-12 in solution with 0%, 1%, and 100% Fetal Bovine Serum (FBS). 
Impedance results were normalized versus the blanks, or the experiments where 
IL-12 concentration equaled 0. Solutions with 0% FBS, simulating purified patient 
samples, was detected with a log/linear concentration-impedance relationship 
between 0.1-1000pg/ml concentration. As interferant was added to create a 
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dilute (1% FBS) complex solution simulating partially purified patient samples, 
the upper concentration range of the log/linear relationship contracted to 
100pg/ml (Fig. 3.11c), with a nonlinear relationship thereafter. Increasing the 
FBS concentration from 1% to 100% (Fig. 3.11a, b) to simulate unprocessed 
patient serum samples, the log/linear range shortened to 0.1-10pg/ml, 
concentration-impedance relationship following a nonlinear trend at higher IL-12 
concentrations. 
 
Fig. 3.11 Background Interaction: Impedance vs concentration and best fit lines for IL-12 in (a,b) 
redox probe with 100% Fetal Bovine Serum (FBS) (c,d) redox probe with 1% FBS (e) redox probe. 
Data adapted from (Bhavsar et al. 2009). 
 
3.3.5 Estimation of IgG Coverage and IL-12 Maximum Binding Concentration 
 The surface area of an electrode, using the working area as 
12.192x12.192 mm2 and a thickness of 25.4 m was calculated as:  
SAelec  = 1x(12.192x12.192 mm)+4 x (0.0254 x12.192 mm) 
 = 1.4988x10-4 m2 
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 The surface area taken up by 1 molecule of IgG (assuming dimensions of 
2x7x10 nm, Wrigley, 1983; Valentine, 1967) would be found from these 
dimensions and how the molecules are attached to the surface. Typical 
assumptions of immobilization of IgG using a cross-linker such as MHDA is that 
one of the antigen binding sites is immobilized so that only one of the variable 
regions is presentable to an antigen. 
SAIgG  =  (1 nm)*(5 nm) = 1.5708x10-17 m2 
 
 Assuming an ellipsoidal arrangement for a protein, an estimated 0.74 
packing can be made (Donev, 2004). Therefore, the maximum amount of surface 
loading the IgG molecules can make on one side of the gold coated silver 
electrode would be: 
Max Coverage = 0.74 x (0.987 x 10-6/(1.5708 x 10-17)) 
  = 4.65 x 1011 IgG molecules on a single electrode 
  
 Verification of adequate amount of IgG in solution comes from the 
protocol for fabrication. Therein, a 1 ml of a 50 g/ml solution of IgG in phosphate 
buffer saline, pH 7.4, was used. First, we must assume IgG has MW = 150 kDa 
 6.022 x 1023 molecules/150,000 gm = 4.0115 x 1018 molecules*gm-1 
 = 0.1 ml x 50 g*ml-1 x 1 gm/(106 g) x 4.0115 x 1018 molecules*gm-1 
 = 2.0056 x 1013 molecules of IgG in solution 
 
 If coat 1 electrode, overnight, this volume, a maximum of:  
= 2.0056 x 1013/ (4.65 x 1011 IgG) 
= >100% of an electrode can be coated.  
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3.4 Discussion 
3.4.1 Impedance and Antibody Immobilization 
 Warburg dominance of the bare electrode (Fig. 3.5a, Fig. 3.6a) equivalent 
circuit model indicated diffusion-limited electron movement and low surface 
impedance compared to solution impedance. The prominence of CPE double-
layer capacitance after MHDA immobilization is indicative of an uneven or 
irregular electrode surface, increasing in relative strength (data not shown) 
through antibody immobilization and exposure to IL-12. 
 As surface accumulation increased, changes occurred in the impedance 
spectra. Most notably, impedance was highest when the electrodes were 
immobilized only with MHDA. The impedance then decreased upon 
functionalization with antibody, only to increase again upon binding with target. 
The consistently-observed (other data not shown) decrease in electron transfer 
resistance and surface capacitance is most likely explainable as the effect of a 
charged molecule (IgG) reducing the surface capacitance effect of a relatively 
nonpolar molecule (MHDA). Coupled with the increased CPE significance and 
the decrease of the capacitive proportion of the CPE, this is possibly indicative of 
mixed immobilization on the surface, with not all available MHDA paired with 
antibody, and of yet more increased roughness as antigen associates with some 
of the available antibodies. The CPE element parallel with a CPE-and-resistor 
(Fig. 3.7a, insert) could indicate a mixed surface wherein one component 
displays pure CPE behavior with emphasis on capacitance, and the other 
component displays CPE behavior with emphasis on resistance, in addition to a 
purely resistive component.  
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3.4.2 IL-12 Detection 
 As expected, impedances increased overall with increasing initial 
concentrations of IL-12. In some equivalent circuit models, Ret increased, 
possibility indicating increased electrode resistance as antigen associated, while 
Rs, indicative of solution resistance, remained relatively constant. The 
increasingly resistive proportion of the CPE was possibly indicative of antigen 
association, in that antigen association could be increasing surface roughness.  
 In addition, a local frequency response maxima was found at 4.54 Hz, 
corresponding with the value found elsewhere (Tlili 2006) and in other 
experiments (not shown). Using this optimal frequency, comparison with blank 
data was used to obtain a lower LOD for the sensor. The resulting lower LOD of 
4.3pg/ml is significantly lower than that reached by most other label free 
impedance biosensors (Fig. 3.1).  
 A clear contrast with state of the art label-free EIS biosensors is the lower 
detection limit and the reduced incubation time. Additionally, the optimal 
frequency of detection is another metric rarely found in literature. In our study, 
the sensor was able to detect IL-12 at physiological ranges, not achieved by 
other unlabeled EIS sensors. Undemonstrated, however, is the ability to 
distinguish between very close levels of IL-12 that would be necessary to 
distinguish between physiological and disease-state levels of IL-12.  
 
 
3.4.3 Multimarker Detection 
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 Five separate cytokine biomarkers were detected in solution by the PCB 
EIS immunosensor. The 5Hz optimal frequency of IL-12 was confirmed, and 
optimal frequencies for four other cytokines were obtained for the first time in the 
discipline. This demonstrates the versatility of the PCB immunosensing system 
when immobilized with different antibodies and tested against different antigen 
types.  
3.4.4 Background Interaction 
 The detection of IL-12 at low levels, even when combined in complex 
solution with FBS, is indicative of the robustness of the immobilization and 
blocking against nonspecific interferants. However, the slope change in the 1% 
FBS and 100% samples was most likely due to background interactions. This 
also decreased the range of log-linear relationship between concentration and 
impedance. The extreme case, 100% FBS, showed an increase in slope, and a 
decrease of detection limit to 10pg/ml. This could be attributed to diffusion issues 
more than nonspecific surface interactions as the controls for 0 pg/ml (not 
shown) showed no significant increase between different FBS concentrations. 
3.4.5 Estimation of IL-12 coverage 
  With an estimate of anti-IL-12 surface coverage, it becomes apparent that 
the IL-12 ranges used may not even approach ranges required for saturation of 
the sensor. This indicates the relationship of impedance to initial target 
concentration is probably not based on saturation of the sensor at any point.  A 
linear relationship between initial target concentration and antibody-antigen 
association may be occurring, and being measured by the system.  
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3.5 Conclusions 
 The results of this study showed that the unlabeled PCB EIS 
immunosensor had a demonstrable lower detection limit of 4.3pg/ml, lower than 
almost all extant unlabeled EIS sensors. This indicates that PCB biosensors are 
capable of rapid detection of biomarkers in low in a label-free manner, indicating 
their suitability for further development. The results also showed that the system 
was tolerant (ie. still sensitive to target when exposed) to background 
interference vis a vis high concentrations of fetal bovine serum. This indicates the 
suitability of the system for testing patient samples with minimal pretreatment. 
The PCB platform testing yielded, for the first time, five optimal frequencies of 
detection for the five biomarkers tested. These frequencies allow the freedom of 
using fixed-frequency impedance analysis on these PCB electrodes over longer 
periods of time. These frequencies could also find use in simultaneous detection 
of multiple targets with one sensor. With the optimal detection frequencies 
known, a frequency sweep would become unnecessary, making instrumentally 
and post-analytically simpler impedance versus time experiments the 
interrogation mode of choice. By immobilizing a sensor with multiple antibody 
types and interrogating it with a multi-frequency convoluted signal, a sample 
could be tested for more than one target in a simultaneous fashion. 
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CHAPTER 4 
GOLD DISK ELECTRODE EXPERIMENTS TOWARDS SIMULTANEOUS 
MULTIPLEXING OF MULTIPLE CYTOKINE BIOMARKERS 
4.1 Introduction 
 Chapter 3 covered studies demonstrating the optimal frequencies of 
detection for several biomarkers. The existence of such optimal frequencies 
implies that, instead of using an EIS frequency sweep, interrogating a biosensor 
at innumerable different AC perturbations, it may be preferable to utilize a single 
frequency for detection, saving time and analysis effort. Furthermore, it should be 
possible to immobilize multiple antibody types on a sensor, and then utilize 
multiple optimal frequencies in a single convoluted signal to interrogate the 
sensor for the presence of several antigens simultaneously. However, to create a 
simultaneously multiplexing impedance biosensor, parameters besides the 
optimal detection frequencies must be determined. One way to do this, and take 
a step towards creation of such a biosensor, is with Impedance-time 
measurements. Where Electrochemical Impedance Spectroscopy (EIS) feeds 
many frequencies through the sensor at a given offset, a fixed-frequency 
impedance-time (Zt) technique feeds one frequency into the system at a given 
DC offset. This is illustrated in Fig. 4.1. 
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Fig. 4.1 Z-t Method: The input voltage vs time data (E-t) (a), is fed through the sensor system (b) 
and then compared (d) to the output E-t (c).  From this, absolute Impedance (Z), and phase angle 
(Φ) vs time are obtained (e). In this example there is change in Z but none in Φ between the input 
E-t and the output E-t.   
 
Fixed frequency methods are not unknown to impedance biosensing. A 
fixed 20kHz signal has been used to interrogate a polyalinine-coated sensor for 
detection of antibody to 500ng/ml (Sergeyeva et al. 1996). Similarly, a fixed 
200kHz signal was used to detect anti-IgG binding on diamond and silicon 
electrodes (Yang et al. 2007). A fixed 20kHz, 10mV signal was used in 
conjunction with a collegen-coated gold electrode interrogating a sample for the 
presence/activity of collagenase down to 0.2 mg/ml (Saum et al. 1998). A fixed 
2954Hz, 10mV signal was used for interrogation of an immunosensor detecting 
2,4-dichlorophenoxyacetic acid, at 100μg/ml (Navratilova and Skladal 2004). A 
1.28GHz, 40mV fixed signal was used to interrogate an affinity nanogap sensor 
for detection of thrombin to determine affinity molecule vs antigen kinetics 
(Schlecht et al. 2006). A 10kHz, 5mV signal was found to be optimal for 
monitoring the growth of Salmonella typhimurium on an interdigitated electrode 
(Yang et al. 2004). Likewise a fixed 1kHz, 50mV signal was found to be optimal 
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for interrogating an impedance sensor detecting Salmonella typhimurum in bulk 
solution (Yang 2008).  
4.2 Methods 
4.2.1 Immobilization 
 Wells (affixed as seen in Fig. 4.5a) (Eppendorf) were cut from 1m 
micropipette tips and hung in an empty tip box.  Electrodes (CH Instruments) 
were polished on 3um, 1um and 0.05um alumina in deionized water on polishing 
pads (Buehler) before sonication in deionized water. CV and EIS were 
determined, and interpreted to evaluate gold surface quality (see 3.2.4, Methods 
of Verification for Electrode Functionalization).  
 Immobilization was generally performed as described in chapter 3 with 
some variations. Briefly, for immobilizing anti-IL-12 IgG, 100μl of a 1mM 16-
Mercaptohexadecanoic acid (16-MHDA) (Sigma) solution in reagent grade 
ethanol was placed into a newly affixed well, and the well covered with parafilm 
to prevent evaporation. The sensors were allowed to set at room temperature 
(RT) for 1h. The surface was carefully rinsed with ethanol and then distilled 
water. EIS was performed to evaluate MHDA immobilization. 100μl of 40mM 1-
Ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) (Sigma), 
10mM N-Hydroxysulfosuccinimide (NHS) (Sigma) solution was placed in a newly 
affixed well. After 1h at RT, the sensor was rinsed in phosphate-buffered saline 
(PBS) buffer. Next, a 100μl droplet of a 50μg/ml solution of anti-IL-12 IgG (R&D 
Systems) in PBS buffer was placed in a newly affixed well on the electrode and 
left at RT for 1h. The sensors were carefully rinsed with PBS and then 100μl of 
1mM ethanolamine (Sigma) was added for 30m at RT to block unreacted 
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carboxyl groups of 16-MHDA activated with EDC/NHS. The blocked sensors 
were washed with PBS and stored in PBS at 4 ºC until future use. 
 4.2.2 Electrochemical Methods 
 As described in chapter 3, all electrochemical methods were performed 
with a CHI 660C potentiostat (CH Instruments) in series with a CHI 684 64-
channel multiplexer (CH Instruments). However, instead of printed circuit board 
(PCB) chips with the reference, working and counter electrodes affixed to the 
same surface, an apparatus was used with a separate gold disk working 
electrode (CH Instruments), platinum wire counter electrode (CH Instruments) 
and Silver/Silver Chloride wire reference electrode.  
 To determine the response of CHI electrodes versus a concentration 
gradient, first fully immobilized electrodes were rinsed and new wells for testing 
affixed. 100μl of each of a gradient of antigen (R&D Systems) concentrations in 
1x PBS were successively placed in the well for one hour incubation. After each 
incubation, the electrode was rinsed and the evaluation well affixed for EIS 
testing in 1x redox probe. After the EIS frequency sweep, the electrode was 
rinsed and the incubation well affixed for the next successive concentration, the 
procedure repeated until the concentration series was complete.  
 For long term fixed frequency over time measurements, fully immobilized 
CHI electrodes were rinsed and new wells affixed. 100μl of 1x redox probe was 
placed in the wells and Zt mode of the CHI 660c potentiostat was initiated at one 
of various frequencies, at DC offset as determined previously by CV. 1μl 
injections of PBS, redox probe, and cytokine solvated in redox probe were done 
at intervals to achieve desired antigen concentration.  
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 For short term fixed frequency over time measurements, fully immobilized 
CHI electrodes were rinsed and new wells affixed. 100μl of each of a gradient of 
antigen (R&D Systems) concentrations in 1x redox probe were successively 
placed in the well. Upon placement of test solution, Zt mode of the CHI 660c 
potentiostat was immediately initiated for a 90-second duration at one of various 
frequencies at a DC offset as previously determined by CV. After the Zt 
interrogation, the electrode was rinsed and the well replaced for the next 
successive concentration, the procedure repeated until the concentration series 
was complete.  
4.2.3 Analysis 
 Evaluation of CVs, Nyquist modeling of EIS data, and determination of 
optimal frequency was done as per the procedure specified in chapter 3. Briefly, 
ZsimpWin software was used to find the best-fitting Nyquist model, and 
parameters with the most significance were plotted against concentration. In 
order to determine the ideal fixed frequency for detection, the raw data and plots 
of frequency versus impedance at different target concentrations were used. A 
plot was made of percent change in impedance over all the cytokine 
concentrations tested versus frequency, as well as a plot of frequency vs the 
coefficient of determination as determined from linear fits of impedance vs 
concentration at every employed frequency. Once optimal frequency was 
determined, plots of impedance versus concentration at said optimal frequency 
were made and evaluated.  
 To evaluate fixed frequency versus time data, models were created in 
Simulink to determine kinetic parameters and modes of action within the 
electrochemical cell.  
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4.2.4 Kinetics models 
 The system to be studied is a non-stirred 100ul cylindrical volume 0.5 cm 
in diameter and 0.51cm depth. Antigen is solvated in aqueous solution, reacting 
with antibody immobilized on an electrode at the bottom of the cylinder. This can 
be approached in one of two ways. First, it could be assumed that the 
association-dissociation reaction at the surface of the electrode is limited by 
diffusion. That is, the potential rate of uptake of antigen by the immobilized 
antibody exceeds the rate at which the antigen reaches the surface. This would 
be called a diffusion-limited model. Alternatively, it could be assumed that the 
rate at which antigen reaches the surface exceeds the potential rate of uptake of 
antigen by that surface. In this model, termed kinetic-limited, the reaction at the 
surface is only limited by the antigen-antibody affinity.  
 At higher surface affinities, whether due to antibody affinity or a higher 
surface concentration of antibody, and where convection effects are negligible, a 
diffusion-limited model would be favored. However, if the sensor system is 
diffusion-dominated, then it should not be assumed that over long periods of time 
and in the relatively large space, that convective effects will not also be 
important. At lower surface affinities or where convection effects are important, a 
kinetic-limited model would be favored. As the patterns present in the data are 
consistent whether at short or long durations of antigen solution exposure to the 
electrodes, as will be shown in the discussion of the binding model in 4.4.1, the 
more likely model is kinetic-limited.  
 Basing a model off of reaction kinetics, a basic dissociation equation, 
where complex (product) AxBy breaks down into x subunits of reactant A and y 
subunits of reactant B 
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      (4.1) 
X has a dissociation constant Kd which is defined as the following (Eq. 4.2), 
where, with brackets denoting concentration, [A] is the concentration of reactant 
A, [B] is the concentration of reactant B, and [AxBy] is the concentration of the 
complex. 
       (4.2) 
 In simple situations, where x=y=1, this formula is simplified. One case 
would be a reaction involving antibodies (Eq. 4.3), where antibody Ab and 
antigen Ag are the reactants, and antibody-antigen complex AbAg is the product.  
                 (4.3) 
 This yields a simpler equilibrium dissociation constant (Eq. 4.4), where 
Kreverse (kr) is the reverse reaction rate constant, and Kforward (kf) is the forward 
reaction rate constant (Eq. 4.4).  
  (4.4) 
 By setting the antibody-antigen complex [AbAg] equal to the surface 
concentration Γ, the surface being where the antibody-antigen complex would be 
located, and removing the equilibrium condition equation rate equation for the 
formation of antibody-antigen complex may be obtained (Eq. 4.5) (Karlsson et al. 
1991).  
        (4.5) 
 To simplify the model, it is useful to assume that the available anti-IL-12 is 
not significantly diminished by binding, that the antigen mixture is homogenous, 
and that the surface is fully covered with anti-IL-12 (ΓAb=1). A simulink model 
69 
 
using these assumptions was created (Fig. 4.2), then resultant proportions of 
occupied antibodies plotted at various initial antigen concentrations and sensor 
exposure times for illustrative purposes.  
 
 
 
Fig. 4.2 Rate-limited Simulink Model: Utilizing Eq. 4.5 (inserted equation), this model assumes full 
surface coverage of the sensor with anti-IL-12, that the available anti-IL-12 is not significantly 
diminished by binding, and that the antigen mixture is homogenous.  
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4.3 Results 
4.3.1 Model Output 
 
Fig. 4.3 Theoretical Binding to the Surface Over Time (Rate-Limited Model): Plots of (Γ) antibody-
antigen complex divided by total antibody versus time as calculated by the Simulink model (Fig. 
4.2), where (a,b) the results for the first 100 seconds are shown, (c,d) the results for the first hour 
are shown, (a,c) all four concentrations are shown, or (b,d) the lowest two concentrations used are 
shown. Initial concentrations include (e) 2.5ng/ml, (f), 250pg/ml, (g) 25pg/ml and (h) 2.5pg/ml.  
 
 To explore the model, sample data was plotted. First, the proportion of 
the surface-immobilized antibodies occupied with antigen as a function of time 
was plotted at initial antigen (IL-12) concentrations of 2.5pg/ml, 25pg/ml, 
250pg/ml, and 2.5pg/ml. This was done over periods of both 100 seconds (Fig. 
4.3 a,b) and 1 hour (Fig. 4.3 c,d). Then, the proportion of antibodies occupied 
was plotted as a function of said concentrations at both 100 seconds and 1 hour 
exposure (Fig. 4.4). Over time, as in-solution antigen was depleted, the rate of 
antibody-antigen complex formation slowed. However, the proportion of 
antibodies occupied at a given time had a linear, first-order relationship with 
respect to initial IL-12 concentration. There was also a linear, first-order 
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relationship between initial binding rate and initial IL-12 concentration. In an 
alternative higher-order model (not shown) where the concentration of available 
surface antibody decreased as it was occupied by antigen, results did not diverge 
by more than 1% at 1 hour exposure until target concentration had exceeded 
50ng/ml.   
 
Fig. 4.4 Theoretical Binding to the Surface Over Concentration (Rate-Limited Model): Plots of 
antibody-antigen complex divided by total antibody (Γ/Ab) (Proportion occupied) versus test 
solution initial antigen concentration (Concentration IL-12) as calculated by the Simulink model 
(Fig. 4.2), concentrations as shown earlier (Fig. 4.3) showing (a) the results after the first 100 
seconds of sensor exposure and (b) the results after the first hour of sensor exposure. Best-fit 
regressions indicated that, for both exposure times, the proportion of antibodies occupied is 
modeled to be directly proportional to the initial concentration of target in solution.  
 
4.3.2 EIS Experiments 
Nyquist plots taken from the AC sweeps of the bare, antibody-
immobilized and biomarker bound (IL-12) CHI electrodes were made (Fig. 4.5). 
Also plotted was the Nyquist of the MHDA immobilization (Fig. 4.6b). Upon 
MHDA immobilization, there was an increase, or shifting of the Nyquist plot to be 
observed.  As antibody was immobilized, the Nyquist plot shifted toward an 
intermediate level of impedance in between that displayed by bare electrodes 
72 
 
and the MHDA-immobilized electrodes. As the antigen molecules bound to the 
immobilized antibody the system reversed, with an increase in the overall signal 
becoming evident. Various concentrations of IL-12 were examined and the 
results plotted (Fig. 4.6c-g). As expected, increasing the target concentration 
resulted in an increasing signal. Over the concentration range used (0-
2500pg/ml) increasing the initial concentration of antigen resulted in increasing 
impedance.  
 
 
Fig. 4.5 Immobilization and Modeling of the CHI Electrode: Immobilization state and corresponding 
data for (a) Bare electrode with data (d) conforming to Warburg model, (b) Anti-IL-12 immobilized 
electrode and (c) IL-12 detecting electrode  with respective data sets (e, f) conforming to an 
equivalent circuit model incorporating constant phase elements.  
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Fig. 4.6 Nyquist Spectra on One Gold Disk Electrode:  Real (Z‟) versus imaginary (Z‟‟) impedance 
for EIS spectra run on one gold disk electrode. Data was taken from the sensor in various states, 
(a) the electrode bare and clean, (b) MHDA Monolayer immobilized on the electrode (c) fully 
immobilized sensor immersed in redox probe with no protein, fully immobilized electrode immersed 
in test concentrations of IL-12 of (d) 2.5pg/ml, (e) 25pg/ml, (f) 250pg/ml and (g) 2500pg/ml.  
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Fig. 4.7 Impedance at 5 Hz: The impedance at 5Hz for the concentration gradient displayed above 
(Fig. 4.6) plotted against (a) concentration of IL-12 and (b) proportion of antibodies occupied by 
antigen (IL-12) as determined by modeling binding relative to concentration and time used (Fig. 
4.4b). Best-fit linear regressions with R2 values above 95% found the impedance(Ω) was equal to 
758.67ln[IL-12] + 4213.2 ohms or equal to 696.43ln(proportion bound IL-12) +13906.  
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Fig. 4.8 Modeled Minimum Detection Time: (a) Modeled 5Hz impedance vs time shown for (c) 
2,500pg/ml, (d) 250pg/ml, (e) 25pg/ml, (f) 2.5pg/ml, (g) 0pg/ml, determined by adapting a model 
parameter-data relationship similar to that in Fig. 4.7b to convert the concentration gradient shown 
in Fig. 4.6. The (b) lower limit of detection (LLD) plotted against time, LLD determined using the 
relative standard deviation for the blank experiments determined in Chapter 3, as well as the 
procedure for determining LLD outlined in 3.3.2.  
 
 Minimum detection times were determined by combining the model with 
data. Model impedance at various time points and concentrations was 
determined by converting the model parameter of [AgAb]/[Ab] via a relationship 
between impedance and the model parameter (similar to that shown in Fig. 4.7b) 
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determined from the concentration gradient shown in Fig. 4.6. This was plotted 
as shown in Fig. 4.8a. It was assumed that the relative standard deviation of the 
blank measures as determined in 3.3.2 could be employed for modeling 
purposes with the CHI electrodes. This RSD was employed with the IUPAC 
method as detailed in 3.3.2 and the modeled 5Hz impedances shown in 4.8a to 
determine theoretical lower limits of detection (LLD) across time points from 1 
second to 1 hour incubation with target IL-12. These results are shown in Fig. 
4.8b.  
 Absolute impedance |Z| at 5Hz was taken from the EIS IL-12 
concentration gradient data and used as a metric for evaluation. Plots were made 
comparing impedance at 5Hz to the concentration gradient and to the 
corresponding proportion of antibodies occupied by antigen as determined by the 
model (Fig. 4.2). Least squares regression was used to determine that target 
antigen concentration and the resulting 5Hz impedance have a positive log-linear 
relationship (Fig. 4.7a), as do the proportion of antibodies occupied by antigen 
and the associated 5Hz impedance (Fig. 4.7b).  
 The maximum impedance response was found to occur at 5Hz (Fig. 4.9). 
This was determined by finding the greatest slope of impedance change over 
log[concentration] change where the linear fit of said slope was still significant.  
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Fig. 4.9 Determination of Optimal Frequency: The greatest slope in impedance vs log concentration 
plots occurs at 5 Hz (a) while remaining in the range of frequencies where there is a good log-linear 
fit to said plots (b).  
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4.3.3 Short Term Zt Experiments 
 
Fig. 4.10 Short-term Impedance-vs-Time: Concentration gradients (0-2500pg/ml) of IL-12 as 
detected by CHI gold sensors interrogated by the Zt transduction technique at (a) 4.63Hz, (b) 
1.18Hz and  (c) 4630Hz, approximately 100 seconds incubation time, output metric absolute 
impedance |Z| (ohms). Impedance obtained from 4.63Hz experiment plotted (d) the proportion of 
antibodies occupied by antigen (IL-12) as determined by modeling (Fig. 4.2) binding relative to 
concentration and time exposed. Best-fit linear regression found the impedance was equal to 
420.09ln[IL-12] + 15956 ohms. Also included in are overlays of the data and best fit line of the (a) 
5Hz (4.54 Hz) EIS data presented in Fig. 4.7a, as well as the (f) 1.18Hz and (g) 4590Hz data.  
 
 Concentration gradients of IL-12 were run against CHI gold working 
electrodes immobilized with anti-IL-12 interrogated with various frequencies 
using the Zt transduction technique with no incubation time. The absolute 
impedance |Z| at 90 seconds was used as a metric for evaluation. Plots were 
made comparing impedance at chosen frequencies to the concentration gradient. 
At 5Hz (4.63 Hz) (Fig. 4.10a), there was a log-linear relationship present between 
initial IL-12 concentrations and impedance. This is also the case at the other 
frequencies  (Fig. 4.10b, c), however with higher baselines compared to signal. 
79 
 
Comparison (Fig. 4.10d) was also made to the corresponding proportion of 
antibodies occupied by antigen as determined by the model (Fig. 4.4a). Least 
squares regression was used to determine that the proportion of antibodies 
occupied by antigen and the associated 5Hz (4.63Hz) impedance have a log-
linear relationship (Fig. 4.10d). Comparing the Zt data and the fixed-frequency 
data resulting from EIS interrogation (Fig. 4.7a), the 5Hz (4.54 Hz) data (Fig. 
4.10e) is similar, with Zt having higher baseline impedance than EIS. At 1Hz 
(1.18 Hz), the EIS data (Fig. 4.10f) had both a greater slope (signal) and lower 
baseline impedance. At 5000 Hz (4590Hz), the log-linear best fit has both a 
higher baseline and a higher slope.  
4.3.4 Long Term Zt Experiments 
 CHI gold electrodes immobilized with anti-IL-12 were run against various 
concentrations of IL-12 achieved via injection of small aliquots, while the system 
was continuously evaluated with the Zt transduction technique at 10Hz. After 
diffusing to the surface, antigen created changes in impedance significantly 
greater than background noise or peaks produced by injections of redox probe 
without IL-12 (Fig. 4.11a). The maximum change in impedance per unit time 
(velocity) resulting from injections of antigen was used as a metric, as was the 
total change in impedance resulting from injections of antigen (peak height) and 
the amount of time passing between injection of antigen and achievement of a 
maximum impedance before the return of the system to equilibrium (time to 
peak).  A similar metric to velocity, the change proportion of antibody immobilized 
on the surface which are occupied with antigen, as calculated by the model  (Fig. 
4.2) (model velocity) was found to have a linear, first order relationship with initial 
antigen concentration. The average of maximum velocities at various 
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concentrations as obtained by the long-term Zt experiments was compared to the 
model velocity corresponding to the test concentrations used, yielding a 
relationship characterizable as linear and first order. A similar metric to peak 
impedance, the maximum proportion of immobilized antibodies occupied by 
antigen after exposure to a concentration of antigen, as determined by the model 
(maximum binding), was also found to have a linear, first order relationship with 
antigen concentration. The average peak impedance as determined by long-term 
Zt experiments at the various concentrations used was compared to maximum 
binding, also yielding a relationship characterizable as linear and first order. 
Finally, comparing time to peak directly to antigen concentration yielded no 
significant linear relationship over the concentrations used.  
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Fig. 4.10 Long-term Zt Experiments: An example of (a) a CHI gold working electrode immobilized 
with anti-IL-12 and exposed to various concentrations of IL-12 antigen via injection, interrogated by 
a fixed frequency (10Hz) at 5mV perturbation, resultant impedance plotted vs time. Labeled on-
chart are injections into the system, which in-system are diluted 100-fold, an example of a peak 
height (impedance increase subsequent to an antigen addition) measurement, and impedance 
velocity (maximum change in impedance/time subsequent to an antigen addition) measurement. 
Contrasting the (b) average maximum measured velocity with the modeled (Fig. 4.2) maximum 
velocities corresponding to tested concentrations of (e) 25pg/ml, (f) 250pg/ml and 2,500pg/ml, 
yields a loosely linear relationship. Contrasting the (c) average peak heights resulting from various 
test concentrations with the modeled maximum proportion of immobilized antibodies occupied by 
antigen corresponding to the test concentrations, a loosely linear relationship is also obtained. In 
comparison of (d) time from injection of antigen to peak impedance directly to the concentrations of 
antigen tested, there is a high baseline to signal ratio, and the relationship is best modeled in a 
nonlinear fashion.  
 
 
4.4 Discussion 
4.4.1 Binding Model 
 In both chapters 3 and 4, when interrogating the sensor with the EIS 
technique, it has been found that the initial concentration of antigen in solution 
and the resultant impedance have a log-linear relationship. In this model, as the 
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surface concentration of antigen at any given time is proportional to the initial 
concentration of IL-12 in a linear, 1st order fashion, the relationship between the 
surface concentration of antigen at impedance is likewise predicted by way of 
comparison to be log-linear. This is further confirmed by the chapter 4 EIS 
results.  
 According to the plotted model, a difference between a blank sample and 
a solution with target would manifest itself in immediate change in the surface 
concentration of target antigen (Fig. 4.3), directly proportional to the initial 
concentration of antigen in solution (Fig. 4.4). Assuming that corresponding 
induced impedances can be distinguished, the model indicates that Zt 
experiments with the shorter incubation time periods could be useful for 
distinguishing between different antigen concentrations.  
 Log-linear concentration-impedance relationships are well documented in 
EIS affinity sensors (Du et al. 2008; Hleli 2006; Lasseter et al. 2004; Tsai et al. 
2011; Xu et al. 2012). In this iteration, the relationship between initial antigen 
concentration and sensor impedance has repeatedly been found to be log-linear, 
as shown in both chapter 3 and 4 data. This indicates that according to this 
affinity model, the relationship between antigen binding and impedance will also 
be log-linear: that is, impedance will be a logarithmic function of antigen surface 
concentration, as seen in Fig. 4.7b and Fig. 4.10d. A direct comparison of model 
and experimental results is seen in Fig. 4.12.  
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Fig. 4.12 Comparison of Experimental and Model Results: Data from (a) EIS experiments showing 
5Hz impedance versus initial IL-12 concentration at one hour incubation, with best-fit equation (Fig. 
4.7a), (b) Model showing proportion of antibodies occupied versus initial IL-12 concentration at 1 
hour incubation, with best-fit equation.  
 
 One alternate model for explaining surface concentration of antigen is a 
steady-state diffusion limited model, as defined by Fick‟s law in one dimension 
(Eq. 4.6), where J is the diffusion flux (mol*m-2*s-1), D is the diffusion coefficient 
(m2s-1), C is the concentration (mol*m-3), and x is the relative position (m). This 
could model the situation where steady-state diffusion occurs within a diffusion 
boundary layer near the electrode, beyond which convection effects dominate.  
x
C
DJ  (4.6) 
 By setting boundary conditions of concentration at the surface of the 
electrode equal to 0, and at distance L from the electrode equal to the initial 
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concentration C0, Eq. 4.7 is obtained, where C(x) is concentration as a function of 
distance from the electrode.  
L
x
CxC 0)(  (4.7) 
 And the corresponding flux is found to be as per Eq. 4.8.  
L
DC
J 0  (4.8) 
 According to this 1-D diffusion model, flux towards the surface will be a 
linear function of the initial antigen concentration, indicating that at any arbitrary 
incubation time, surface concentration of antigen will also be a linear function of 
initial concentration. This is similar to the result obtained by the kinetic model, 
and thus presenting the same conundrum of surface impedance increasing with 
the log of the surface concentration of antigen.  
 In three dimensions, and modeling the electrode surface as a 
hemisphere, a steady-state diffusion results in the flux as seen in Eq. 4.9, 
adapted from Crank (Crank 1975), where Qt is the amount of solute (antigen) 
reaching the electrode in a given amount of time t, a is the radius of the 
electrode, b is the distance from the electrode (a radius) at which bulk 
concentration C0 is reached, and D is the diffusion coefficient.  
04 C
ab
ab
DtQt  (4.9) 
 Here, the amount of antigen at the surface is also a linear function of the 
surface concentration. Non-steady-state diffusion effects are deemed unlikely as 
an explanation for this relationship as well, as the relationship is observed at both 
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brief intervals (90-100 seconds) (Fig. 4.9a) and longer durations (1 hour) (Fig. 
4.7a) of incubation.  
 Otherwise, although the Nyquist plots do not conform to an equivalent 
circuit indicating the presence of Nernst impedance, a Nernst impedance is one 
possible mechanism creating the log-linear relationship between initial solution 
concentration of antigen and resultant impedance. This would be possible if the 
reference is off of formal potential and, by depleting one of the redox probe 
species, resultant current is limited by diffusion through the biomolecule-
immobilized surface. By increasing surface concentration (and hence physical 
blocking), the limited redox species would be decreased linearly, and impedance 
increased logarithmically. This type of mechanism could be detected by using 
fluorescently labeled antigen in conjunction with impedance sensing, or by 
measuring the concentration of antigen in solution after removal from the sensor.  
 Another possible mechanism explaining the relationship would be 
saturation of surface antibody limiting the surface concentration, thereby 
indicating a linear bound-antigen impedance relationship. With an antibody 
population of sufficiently heterogenous affinity, saturation could create a surface-
binding-to-initial concentration proportion resembling a logarithmic relationship 
over several decades of concentration. One way to determine if this is occurring 
would be by changing the antibody source, or deliberately hobbling affinity. 
Again, this could be detected through fluorescent labeling of target antigen, or 
measurement of test solution concentration after removal from the sensor.  
4.4.2 EIS Experiments 
 The pattern of changes in Nyquist spectra during immobilization and 
experimentation confirmed patterns observed in chapter 3. Most notably, 
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impedance was higher when the sensor was immobilized only with 16-MHDA 
than when the sensor was also immobilized with antibody. This consistently-
observed decrease in electron transfer resistance and surface capacitance is 
most likely explainable as the effect of a charged molecule (antibody, in this 
case) reducing the surface capacitance effect of a relatively nonpolar molecule 
(MHDA).  
  In contrast to state of the art label free EIS biosensors (see 3.1.1), label-
free EIS detection on chi electrodes demonstrated generally lower levels of 
antigen detected, and the potential for a shorter incubation period. The log-linear 
relationship between antigen concentration and electrode impedance confirms 
the results of chapter 3, and here it is further explained in light of the model, with 
a possible empirical relationship between binding to the sensor surface and 
observed impedance. Overall, these EIS results indicate the cross-platform 
viability of the techniques used.  
 The optimal frequency results confirm published results (Bhavsar et al. 
2009; Fairchild et al. 2009) and the IL-12 optimal frequency results presented in 
chapter 3. The optimal frequency results also the indicate cross-platform viability 
of the optimal frequency statistic. Modeling of the minimum detection time 
utilizing this data indicates how the lower limit of detection is affected by 
alteration of antigen-sensor exposure time. This analysis indicates lowering 
incubation time to very short durations may be feasible without compromising 
lower LOD goals.  
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4.4.3 Short Term Zt Experiments 
 Fixed frequency impedance experiments of 90-seconds duration further 
confirmed the optimal frequency concept (Fig. 4.9). Below optimal frequency, 
increases in impedance over target concentration are observable, but there is 
what could be a marked saturation effect. Above the optimal frequency, 
impedance does not correlate strongly with concentration, and the baseline 
impedance makes up a larger and larger proportion of the signal. Using Zt at the 
optimal frequency, the log-linear relationship between antigen concentration and 
impedance strengthens, confirming this association. This was further investigated 
by comparison with the model, indicating a possible empirical relationship 
between bound antigen and impedance as measured by Zt. The results also 
demonstrated Zt detection below the levels observed by current fixed-frequency 
impedance systems (see 4.1). Comparison between Zt, with no incubation time, 
and EIS performed after 1 hour incubation revealed that similar detection 
capability was achieved.  
4.4.4 Long Term Zt Experiments  
 Unlike other experiments, long-term measurement of impedance at a 
fixed frequency showed a linear relationship between concentration and 
impedance, demonstrated both with the maximum rate of impedance increase 
and the total impedance increase provoked by the introduction of antigen, and 
similarly holding a linear relationship with corresponding model metrics. 
However, perturbing the system with a DC offset and low frequency AC signal 
continuously for hours could have had unforeseen effects. Using a wider range of 
concentrations would have been helpful in understanding this further. However, 
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utilizing this technique, the effects of injection with lower concentrations could not 
successfully be separated from background noise. Additionally, with manual 
introduction of antigen using small aliquots as not to perturb the fluid, significantly 
higher concentrations could not be achieved with commercially available 
concentrations of IL-12. Automated sample handling would assist in employing 
higher concentrations with this technique.  
 The time between introduction of sample and resulting peak impedance 
did not vary greatly by concentration used. This is in accordance with the model, 
which predicts that the amount of antigen bound at any given time relative to the 
initial antigen concentration introduced should be invariant. However, if 
equilibrium binding is indicated by peak impedance, then the model is inaccurate 
in that it predicts a greater amount of time until a near-equilibrium condition is 
reached. Additional factors present could be investigated by utilizing labeled 
antigen in simultaneous conjunction with this technique.  
4.5 Conclusions 
 This study has presented impedance biosensing experiments using 
modeling, frequency sweep and fixed-frequency methods. Rapid detection of IL-
12 was suggested with the kinetic sensor model, and confirmed with fixed 
frequency experiments, and confirmed again by modeling of minimum detection 
time. This informs the goal of utilizing fixed frequency methods for rapid, 
simultaneously multiplexed biosensor transduction. The frequency sweep 
experiments on the alternate platform demonstrated the cross-platform 
robustness of the experimental procedure. The frequency sweep results also 
confirm an optimal frequency of 5Hz for IL-12, as determined in chapter 3. 
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Optimal detection frequencies for biomarkers are necessary for simultaneous 
detection of multiple biomarkers with one sensor immobilized with multiple 
antibodies. When interrogated with multiple (optimal) frequencies over time, such 
sensors would respond with greater change in impedance at those optimal 
frequencies corresponding to the biomarkers with greater concentration in test 
solution.  
 
90 
 
CHAPTER 5 
DESIGN OF PROTOTYPE SIMULTANEOUS MULTIPLEXING DEVICE 
5.1 Introduction 
 One of the pervasive challenges in drug therapeutic efficacy studies, 
proteomic or genomic biomarker discovery, personalized medicine, etc., is in 
multiplexing the assay to allow for the detection of a set of biomarkers that 
identify a disease signature (Sluss 2008). These kinds of studies require the use 
of high throughput assays where tens of thousands of targets can be investigated 
simultaneously and as rapidly as possible (Borrebaeck 2007). Also, single 
marker studies have led to the conclusion that a multiplexed system looking at 
more than one marker can improve specificity and sensitivity over a single 
marker alone in cancers (Havrilesky et al. 2008; Molina et al. 2005; Tchagang et 
al. 2008). Many limitations must be overcome to enable a multi-marker, rapid, 
label-free, simple-to-use Point-of-Care (POC) device that works with complex 
solutions like blood samples. There have been some creative solutions to these 
issues including multiplexing and labeling of the target (Pregibon et al. 2007), 
downstream processing (Bensch 2006), etc. However, much of the multiplexing 
and instrumentation issues have not yet been resolved and the future looks even 
more demanding. In the early stages of personalized medicine, a push has been 
made for high throughput screening of patient samples with respect to drug 
safety (Katsanis et al. 2008) and to therapeutic and diagnostic evaluation 
(Bonnefoy 2008). Limitations in these methods also typically include: 
instrumentation, display, sample preparation, size, costs, complexity, and/or a 
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requirement of labeling (Borrebaeck 2007; Pregibon et al. 2007). Many limitations 
must be overcome to enable a multi-marker, rapid, label-free, simple-to-use POC 
device that works with complex solutions like blood samples. These limitations 
include a lack of simplified operation, multiplexing targets, ambient temperature 
reagents, and rapid assay, among others (Lewandrowski 2008; Nichols 2008).  
 Multiplexing sensors by innovative means would reduce instrumentation 
demands, thereby lowering costs, speeding up the assays, and directly impacting 
health. This could be accomplished by a multisine impedance immunosensor 
with „tuned‟ antibodies coupled with an appropriate potentiostat and software to 
not only multiplex and encode a perturbation signal but also to deconvolute the 
output. This would be done so that multiple molecular recognition elements and 
targets could be interrogated on a single sensor using a rapid and label-free 
approach.  
 Building upon impedance immunosensing experiments with printed circuit 
board (PCB) electrodes presented earlier, Chapter 4 discussed impedance 
immunosensing experiments on CH instruments (CHI) gold disk electrodes, 
including electrochemical impedance spectroscopy (EIS), impedance vs time 
measurement using a fixed frequency (Zt) in the short and long term. 
Additionally, Chapter 4 discussed equivalent circuit modeling of the electrode 
surface and kinetic modeling of electrode affinity. Towards the project‟s its 
ultimate goal, that of a rapid, simultaneously multiplexing impedance 
immunosensing system, earlier experiments established that PCB biosensors 
were capable of rapid detection of biomarkers in physiological and disease-state 
concentrations in a label-free manner and with minimal sample preparation. 
Chapter 4 experiments also brought the project towards this resolution. The 
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immunosensing EIS experiments on CHI electrodes versus concentration 
gradient demonstrated cross-platform robustness of the sensor preparation and 
detection technique, and confirmed optimal frequency, the former useful for the 
overall goal by demonstrating that alterations in sensor composition and 
alterations in sensor and solution well geometry were tolerable, while the latter 
was useful for the overall goal by demonstrating the frequency-dependant nature 
of the change of impedance due to binding of target antigen. The kinetic model of 
affinity biosensing for the system was useful for the overall goal by showing that 
under at least one interpretation it should be possible to distinguish between 
different concentrations of target in a short time, and over a wide range of 
concentrations. The short term Zt experiments were useful for the overall goal by 
demonstrating detection of target antigen was possible within 90 seconds at 
optimal frequency, in conformation with the model. The long term Z-t experiments 
were useful for the overall goal by demonstrating that an impedance response 
above baseline could be provoked by introduction of target antigen to the solution 
well, also in conformation with the model.  
 Chapter 5 discusses the design of an impedance immunosensing system 
that includes new features for additional utility, such as provisions for automated 
sample handling and testing included in the redesign of the PCB sensor wells 
and holder. However, this design also utilizes the aforementioned results in 
specific ways. Having shown the Zt method (introduced in chapter 4 section 4.1) 
can be utilized at specific frequencies for favorable affinity detection within a 
short period of time, this impedance sensing technique is elaborated upon to be 
able to interrogate a sensor for multiple kinds of affinity interactions. This end 
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requires alterations of both the data handling and the potentiostat itself, and an 
introduction to various ways that it could be accomplished.  
5.1.1 Analog and digital convolution/deconvolution 
 
Fig. 5.1 Schema of Optimal Detection Frequencies: IL-12 at 5Hz, IFN-g at 9.77Hz, TNF-a at 
17.44Hz, IL-2 at 31.5Hz, and IL-10 at 117.2Hz. It has been demonstrated that these frequencies 
can be „tuned‟ farther apart by coupling nanoparticles to the antibodies prior to sensor 
immobilization (Demirok 2010).  
 
 The optimal frequencies, determined in the results presented in chapter 3 
and confirmed in the results presented in chapter 4, crudely amount to the stop 
band (i.e. frequency band of increased impedance) of their respective antigen-
antibody interaction at the sensor surface when interrogated by an ac voltage 
sweep. A representation of these optimal frequencies can be seen in Fig. 5.1. 
Several antigen-antibody pairings with (or modified to have) distinct optimal 
frequencies could be immobilized together on the sensor surface to create a 
sensor with multiple optimal frequencies, each stop-band corresponding to the 
presence of a particular antigen target in solution. This single electrode could be 
interrogated for multiple targets with EIS, each frequency targeted for a brief time 
and at different points in time, with much time and data wasted on irrelevant 
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frequencies. Alternatively, it could also be interrogated sequentially at the optimal 
frequencies, an AC voltage for each passed through the sensor one after the 
other, however foregoing the opportunity for continuous impedance data over 
time. Some additional signal processing presents the opportunity of a further 
alternative. The multiple-antibody-immobilized working electrode could be 
interrogated with simultaneously at all optimal frequencies, the AC voltages 
multiplexed into one convoluted signal, as illustrated in Fig. 5.2. The output AC 
signal would then be deconvoluted, as illustrated in Fig. 5.3, before comparison 
with the individual input signals for evaluation, as illustrated in Fig. 5.4. The 
impedance increases at frequencies of concern, corresponding with different 
antigen-antibody pairings, could then be monitored continuously over the span of 
time of the experiment.  
 
Fig. 5.2 Convolution and Input into the Sensor: a (a) low frequency, high amplitude waveform (a) is 
combined with a (b) higher frequency, lower amplitude waveform to form the input voltage (c) Vin 
for multisine Zt measurement to be input to the sensor immobilized with different antibody types.  
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Fig. 5.3 Output Signal Deconvolution: The (a) sensor immobilized with multiple antibody types 
outputs, through the potentiostat, a voltage signal (b) Vout which is then filtered into its (c) low 
frequency and (d) high frequency components 
 
Fig. 5.4 Comparing Vout with Vin: Comparison of output waveforms at (a) high and (c) low 
frequencies with their respective (b) high and (d) low frequency inputs (see Fig. 4.1 for method) 
resulting in data revealing (e) impedance of the sensor over time for multisine Zt at (f) high and (g) 
low frequencies.  
 To accomplish this signal processing, various approaches may be taken. 
Convoluting AC voltages into a single multiplexed, multisine input signal can be 
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accomplished post-generation by analog methods, or pre-generation by digital 
control. Deconvolution of the output signal likewise could be performed prior to 
analog-to-digital conversion using analog circuit components, or after conversion 
by digital processing. For example, in order to simulate an EIS frequency sweep 
in a shorter amount of time, multisine EIS systems generally interrogate a system 
with complex AC signals which are then interpreted via digital signal processing 
(Blajiev et al. 2006; Creason and Smith 1972), though these devices do not 
posses multisine Zt capability.  
 Crudely, analog signal processing could be anything that affects the 
signal- for example a stiff wall acts as a low pass filter for sound waves, leaving 
low frequency sound waves with higher gain than those at high frequency. 
However, for electrical signals, analog signal processing uses passive and active 
circuit elements, like as resistors, capacitors, inductors, operational amplifiers 
and non-linear devices. Output is obtained in real time, and is continuous rather 
than sampled. They can be easy to assemble and inexpensive, but, especially 
with higher order filters, difficult to maintain, calibrate and modify (Skolnick and 
Levine 1997). Furthermore, an ideal first order filter only has fourfold power loss 
every octave of frequency off the target frequency.  
 A digital approach has some distinct advantages over analog 
approaches. With analog signal processing, the system has to be redesigned 
every time the specifications are changed. Design components may not be 
available and the processer must use components with parameters within some 
tolerance. Components may suffer from parameter variations due to room 
temperature, humidity, supply voltages, and many other aspects, such as aging, 
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component failure. In contrast, digital signal processing can be used to 
implement different versions of a system by changing the software on the 
processor, and will vary less due to environmental circumstances, thus exhibiting 
flexibility and repeatability. However, digital signal processing consists of 
numerical computations and there is no guarantee that the processing can be 
done in real time, i.e. it can lag. In addition, if the input and the output signals are 
analog, then an analog-to-digital converter (ADC) and a digital-to-analog 
converter (DAC), which can be expensive, are additionally needed to implement 
analog processing by digital means (Yarlagadda 2010).  
5.1.2 Potentiostats 
 The potentiostat has two tasks: To measure the potential difference 
between working electrode and reference electrode without polarizing the 
reference electrode, and to compare the potential difference to a preset voltage 
and force a current through the counter electrode towards the working electrode 
in order to counteract the difference between preset voltage and existing working 
electrode potential. 
 This is done using an operational amplifier (OPA). When the working 
electrode is connected to the non-inverting input (+), the reference electrode to 
the inverting input (-), and the counter electrode to the output, the difference 
between working electrode and the reference electrode will be amplified and 
inverted by the OPA. By feeding a matching current to the counter electrode, 
current passes through the electrolyte to the working electrode. This polarizes 
the working electrode so that the difference between the reference electrode 
input and the working electrode input is zero. This can keep the potential of the 
working electrode on the potential of the reference electrode. A voltage source 
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could be inserted in series between the reference electrode input and the 
reference electrode to shift the potential of the working electrode to a different 
value referring to reference electrode. Measuring the voltage across a resistor in 
the counter electrode wiring, proportional to the current flowing, could be used to 
measure the current through the counter electrode. Alternatively, the same could 
be done in the working electrode wiring (Doelling 2000).  
 
Fig. 5.5 Schematic of a Potentiostat: Device settings are input by the user, controlling the processor 
to output a digital signal which is converted into analog signals. The analog signals have their high-
frequency range filtered out before forming the voltage offset between the counter and working 
electrodes. Current passing between the counter and working electrodes is converted to voltage, 
which then has high-frequency components filtered out before being reconverted to digital and 
passed to the processor. Data output is returned to the user.  
5.2 Device 
 The sensor and holder designs build off of existing PCB array designs. 
The individual multiplexed, multisine sensor for POC and laboratory use, as seen 
in Fig. 5.6a, is dimensioned to fit a plate with a well as seen in Fig. 5.6b-c. With 
an elastic polymer on the bottom layer, the well plate seals to the top of the PCB 
array, closing inflow and outflow channels milled into the bottom of the well plate. 
Inflow and outflow ports at the edges of the well plate connect with respective 
ports on the individual sensor holder, and thereby to peristaltic or equivalent 
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pumps for the purpose of carrying sample to and from the wells. The holder is 
similar to the array holder pictured in Fig. 5.9, but scaled for a single sensor.  
 But the single-sensor is not the only useful configuration for this device. 
The PCB array configuration, for the purpose of testing larger numbers of 
biomarkers, for the most part for experimental uses, may be seen in Fig. 5.6d 
and 5.7. This array is dimensioned to fit a plate with an array of wells, as seen in 
Fig. 5.6e-f and Fig. 5.8. Similarly to the single sensor, the array well plate seals 
to the array, also completing inflow and outflow channels for each of the 
individual wells, which can connect with fluid channels in the electrode holder 
seen in Fig. 5.9.  
 
Fig. 5.6 Electrode and Well Plate Designs: a (a) top view of a single sensor for use with a well plate 
seen in (b) top and (c) front views, for use in multisine Zt, adjacent to a (d) top view of a sensor 
array for use with a well array plate seen in (e) top and (f) front views, also for use in multisine Zt.  
 
 Manufacturing of this device could be accomplished by means available 
at Arizona State University. To manufacture the single and array multiplex 
sensors, first the layouts, for example as seen in Fig. 5.8, would be printed onto a 
transparency and carefully aligned to a pre-sensitized copper-clad board, which 
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would then be exposed to UV light. After development and removal of exposed 
photoresist and copper, nickel and gold would be electroplated onto the electrode 
and lead portions of the device, but not onto the contact terminals. Subsequently, 
Ag/AgCl would be plated onto the reference electrode. Finally, the electrodes 
would be immobilized with biomolecules, first with a thiol monolayer, then linking 
the desired antibodies through EDC/NHS chemistry. These manufacturing 
methods are detailed in chapter 3. To manufacture the well or well array as seen 
in Figs. 5.6 and 5.8, two thin sheets of plexiglass or equivalent plastic would first 
be obtained, of thickness 0.025" and 0.05". These would be milled with the well 
and fluid channel features, then the two layers adhered with a permanent weld. 
At that point, a thin elastic polymer would be adhered to or created on the bottom 
of the well layer.  
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Fig. 5.7 Dimensioned Array for use in Multisine Zt: Etched on copper clad board, (bottom) contact 
leads for attachment to an edge connector are connected through leads of 0.01" width to (top) 5 
sets of 3 electrodes, which are plated in nickel and then gold. Each set has a (left) counter 
electrode (center) working electrode and (right) reference electrode, the reference electrode further 
coated with Ag/AgCl.  
 
Fig. 5.8 Dimensioned Well Plate Array with Flow Channels: Wells of 100ul volume, centered over 
each 3-electrode set, are connected to individual flow channels of 0.02"x0.025" cross section.  
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Fig. 5.9 Electrode and Holder: The (a) electrode array inserted in to an EDAC edgeboard connector 
type EDC395602-ND, ready for placement on the (b) array holder, the array (c) after placement into 
the holder 
  
Adaption of the apparatus for data processing can be handled several ways. 
Generation of the convoluted signal can be handled by a digital waveform 
generator. By placing band-pass filters in series with the output line, as seen in 
Fig. 5.10, the Vout signal can be split into its component parts prior to comparison 
with the input Vin component by digital signal processing methods. Alternately, 
the Vout signal could be split after analog-to-digital conversion using digital signal 
processing methods. Both approaches necessitate the construction of a 
potentiostat device and the creation of a data analysis program. As a third option, 
some custom-built potentiostats for performing multisine EIS could theoretically 
also perform multisine Zt experiments with minimal modification (Pettit et al. 
2006; Polonschii et al. 2007). These could be acquired by purchase. The single 
electrode or electrode array, with holders, may also be used with a commercial 
potentiostat such as a CHI-660c for interrogation by other electrochemical 
transduction methods.  
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Fig. 5.10 Modified Potentiostat for Multisine- 2 Waveforms: The potentiostat as described in Fig. 
5.5, excepting that the output signal Vout is split before band filtering to obtain AC voltages at 
particular frequencies, To take advantage of this feature, the processor would output a multisine 
signal through the potentiostat to the electrodes. This particular device would be capable of 
handling a sensor with two different optimal frequencies.  
 
 For use after preparation of all components, the sensor (or array), the well 
plate (or well array plate), edge connector and holder would be assembled as 
seen in Fig. 5.9. In this configuration, the contact terminals of the sensor(s) form 
electrical connection with contacts in the edge connector, linking the sensor 
surfaces and the solder tails of the edge connector. Also, seating of the well plate 
on the sensor(s) would form wells connected to channels in the plate, which in 
turn would be connected to inflow and outflow fluid leads in the holder.  
 The inflow fluid leads would then be connected to a peristaltic pump for 
liquid inflow without direct contact without the pump machinery. At their termini, 
the inflow fluid leads could be attached to any fluid required, or to y-connector to 
rapidly and efficiently select between different fluid sources. The outflow fluid 
leads would connect to a disposal container. The edge connector solder leads 
would be connected to the appropriate respective terminals of a potentiostat, 
whether for multisine Zt or for other techniques. The potentiostat, in turn, would 
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be connected to a personal computer with controlling software and data analysis 
software. For POC use, the potentiostat and holder and edge connecter could be 
made as one piece, simplifying the use of the device when specialized for one 
task.  
5.3 Conclusions 
 Creating a device with increased automation of sample handling and 
testing has the advantages of reducing variability due to exogenous factors and 
increasing the rapidity of the assay, and the side-benefit of easing sensor or 
sensor array fabrication. With easier fabrication, the device will have the further 
advantage of low cost. Furthermore, by employing simultaneous multiplexing 
through multisine perturbation, multiple types of antibody-antigen affinity binding 
events may be observed in real time, reducing the number of sensors, and 
consequently the amount of test sample used, in the detection and quantification 
of multiple biomarkers. This also reduces the amount of time consumed and/or 
peripheral equipment such as potentiostats and computer terminals required, 
easing convenience and making practical POC use. Besides POC, this system 
would have application in biomarker research as well as for basic biosensor 
development, being capable of observing impedance over time associated with 
recognition events. 
105 
 
CHAPTER 6 
SUMMARY AND FUTURE WORK 
6.1 Introduction 
 Costs associated with diagnosis have been growing at a faster pace than 
overall US healthcare costs (Feldman 2009; NHSG 2010). This trend results from 
the increasing employment of complex, powerful laboratory testing in medical 
diagnostics versus primary physician screening (Feldman 2009). This highlights 
a possible opportunity for systems which could bridge the gap between low and 
high end diagnostic methods, being both sufficiently easy to use and of sufficient 
diagnostic utility to act as an intermediate diagnostic step between point of care 
primary physician screening and intensive testing requiring specialist attention. 
Biosensors for the detection of bodily fluid biomarkers are one technology which 
may be used to exploit this opportunity (Rapp et al. 2010), to both speed 
diagnosis and to reduce the effort involved. Medical conditions for which 
quantification of multiple bodily fluid cytokine biomarkers would be diagnostic or 
prognostic include Multiple Sclerosis (Giovannoni et al. 1997; Hollifield et al. 
2003; Nicoletti et al. 1996; Woodroofe et al. 1991), cancers (Linkov et al. 2008; 
Molina et al. 2005), Rhumatoid arthritis (Hueber et al. 2009; Rioja et al. 2004), 
Irritable Bowel Syndrome (Scully et al. 2010), Inflammatory Bowel Disease (Alex 
et al. 2009; Alex 2008), Lupus (Chun et al. 2007; Manukyan et al. 2010), trauma 
(Maier et al. 2007), sepsis (Marchant et al. 1995; Oberholzer et al. 2001; Sherwin 
et al. 2008), and organ rejection (Hassan et al. 2006; Platz et al. 1996).  
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 A biosensor is “a device that uses specific biochemical reactions 
mediated by isolated enzymes, immunosystems, tissues, organelles or whole 
cells to detect chemical compounds usually by electrical, thermal or optical 
signals,” (Nic 2010). If limited to purpose-built examples, the first example, in 
1962, would be a glucose detection biosensor utilizing Glucose-Oxidase enzyme-
based detection (Clark 1962). Biosensors have proliferated widely since then, 
and count among their variety systems which employ various kinds of recognition 
elements (Nicu and Leïchlé 2008; Ronkainen et al. 2010), immobilization 
methods (Mayes 2002; Ulman 1996), and transduction methods (Aoyagi and 
Kudo 2005; Campbell and Mutharasan 2008; Janshoff et al. 1997; Leonard et al. 
2004; Lowe 2008; Mathew and Alocilja 2005; Nicu and Leïchlé 2008; Song et al. 
2006). One particular category of transduction method, electrical, includes 
impedimetric techniques (Daniels and Pourmand 2007), which may be used in 
conjunction with affinity recognition elements and self-assembled monolayer 
immobilization for rapid, sensitive detection of target analytes (La Belle et al. 
2007). In impedimetric techniques a system is interrogated with an AC voltage in 
combination with a DC offset, and the comparison of the output with the input 
obtaining impedance. Electrochemical Impedance Spectroscopy (EIS) is an 
impedimetric transduction technique wherein this comparison is repeated at 
different frequencies, and has been utilized in biosensing for detection of target 
antigen down to concentrations of 1pg/ml (La Belle et al. 2007; Tsai et al. 2011). 
The impedimetric impedance-time (Zt) technique instead interrogates a system 
with one frequency for a given amount of time. Using impedimetric techniques, 
specific frequencies have been found where the change in target concentration 
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affects the impedance of an affinity biosensor most strongly (Lasseter et al. 2004; 
Yang et al. 2004; Yang 2008).  
 Diagnostic and research biomarker sensing systems have value added 
when multiplexing, for identifying a disease signature clinically or for research 
purposes in a laboratory setting, investigating more markers simultaneously is 
useful (Borrebaeck 2007; Sluss 2008). For multiplexing in an impedimetric affinity 
biosensor, a system could be interrogated with multiple frequencies at the same 
time, or simultaneous multiplexing.  
 With the long term goal of the design of a simultaneously multiplexing 
impedance affinity biosensor, in the current work three studies were performed in 
regard to impedance immunosensors. These studies were done to determine the 
parameters required to develop a simultaneous multiplexing impedance affinity 
sensor, in short, to find the optimal frequencies for a selection of biomarkers, to 
demonstrate the effectiveness of EIS and Zt techniques for affinity sensing, to 
determine the incubation time required for effective sensing and, finally, to design 
a system to be used as a simultaneously multiplexing impedance affinity 
biosensor. The conclusions from the three studies presented in this dissertation 
are summarized below and future avenues of research discussed.  
6.2 Summary 
 Specific aim 1 was to test the hypothesis that various cytokines induce 
experimentally determinable frequencies of response when captured by affinity 
molecules immobilized to the surface of a biosensor. In chapter 3, this hypothesis 
was tested by developing printed circuit board (PCB) 3-electrode immunosensors 
and interrogating them with EIS in the presence of concentration gradients of 
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antigen corresponding to the immobilized antibody. This study showed that five 
different cytokine biomarkers had distinct „optimal frequencies‟ in relation to 
impedimentric sensing. The data also showed that the PCB EIS immunosensor 
had a demonstrable lower detection limit of 4.3pg/ml when studying the cytokine 
Interleukin-12 (IL-12), and that the system was also tolerant (ie. still sensitive to 
target when exposed) to background interference vis a vis high concentrations of 
fetal bovine serum. In addition, equivalent circuit models of the data revealed that  
 Specific aim 2 was to test the hypothesis that rapid detection of cytokine 
analytes via impedance immunosensing could be done without greatly sacrificing 
sensitivity. The second study demonstrated that distinct detection of different 
concentrations of IL-12 could be accomplished within 90 seconds of exposure. 
This was shown via kinetic modeling and confirmatory Zt studies. The data 
showed that the immobilization method and electrochemical techniques were 
robust across platforms. This was demonstrated via EIS immunosensing vs 
concentration gradients of antigen, and subsequent equivalent circuit modeling. 
The data also showed that interrogating the immunosensor with a fixed, optimum 
frequency could be used for sensing target antigen. This was demonstrated via 
Zt immunosensing at various frequencies vs concentration gradients of antigen.  
 Specific aim 3 was the design of a multiplexing impedance immunosensor 
for the simultaneous quantification of biomarkers of multiple types, its method of 
manufacture and its method of use. The second study presented a device that 
reduced variability due to exogenous factors and increased rapidity of assay with 
eased sensor fabrication. This was shown via its increased automation of sample 
handling and testing. The second study also presented a way to observe multiple 
types of antibody-antigen affinity binding events in real time, reducing the number 
109 
 
of sensors and target sample used in the detection and quantification of multiple 
biomarkers. This was achieved by presenting methods for simultaneous 
multiplexing through multisine perturbation of a sensor. This would also improve 
the suitability of the sensor for POC multiplex detection of disease biomarkers.  
6.3 Conclusions 
 In this dissertation, the overall goal was experiments toward the creation 
of a multiplexing immunosensor for the quantification of cytokine biomarkers. 
Through utilization of rapid, simple and relatively inexpensive impedance 
biosensing, the creation of a „good enough, easy enough‟ device was a 
promising target. The first study focused on determination of perturbation 
frequencies at which impedance changes the most over the concentration 
gradient, i.e. optimal frequencies. This study demonstrated, for apparently the 
first time, the optimal frequencies of the cytokine biomarkers Interleukin-10 (IL-
10), Interferon gamma (IFN-y), Tumor Necrosis Factor alpha (TNF-a), and 
Interleukin-2 (IL-2). The first study also demonstrated label-free EIS biosensing 
of biomarkers, in this case IL-12, to a lower LOD than in almost all current 
literature, in addition to showing a log-linear relationship between impedance and 
concentration over five decades of concentration. The first study also 
demonstrated detection of target to low levels even in the presence of complex 
solution. Utilizing the optimal frequencies determined and sensing techniques 
practiced in the first study, the second study was focused on determining the 
efficacy of rapid, label-free fixed-frequency impedance biosensing. The second 
study demonstrated that rapid quantification of target antigen with fixed-
frequency impedance biosensing was theoretically possible and achievable in 
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reality. In the course of the second study, it was also demonstrated that the 
results of the EIS technique were consistent across transition to a different 
sensing platform, across transition to different exposure times, and even across 
transition from frequency sweep impedance sensing to fixed frequency 
impedance sensing. Utilizing the knowledge of distinct optimal frequencies and 
tolerance of impedance immunosensing to interferants determined in the first 
study, and the demonstration of the efficacy of short-term fixed frequency 
impedance sensing for detection, the third study was focused on designing a 
multiplexing impedance immunosensor for the quantification of biomarkers in 
bodily fluid. The third study demonstrated designs for simultaneous, multisine 
detection of multiple biomarkers on one sensor utilizing one fixed, complexed 
perturbation signal. and the third study also demonstrated an array scaleup 
thereof for detection of even greater numbers of different antigens, and for 
replication or other experimental purposes. Successful development of this 
system would realize the creation of an invaluable tool for biomedical study and 
medical diagnosis.  
6.4 Future Experiments 
 Studies utilizing a device for simultaneous multiplexing invite the 
investigation of a disease for which multiple biomarkers may be measured for 
improved diagnosis or prognosis. For example, in one study patients with 
malignant thyroid tumors have been shown to be best distinguishable from 
normal controls with a model utilizing a concentrations determined for a group of 
4 among 19 cytokines surveyed in serum. These four were Interleukin-8 (IL-8), 
IL-12, epithelial growth factor (EGF), and hepatocyte growth factor (HGF). 
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Median quartiles of serum concentration as detected by fluorescent 
immunoassay were, for normal subjects compared to patients with malignant 
thyroid tumors; for HGF, 148.9-248pg/ml versus 67-178pg/ml, for IL-8, 3.49-
4.19pg/ml versus 2.71-4.51pg/ml, for IL-12p40, 35-66.4pg/ml versus 34.5-
84.1pg/ml, and for EGF, 28.04-56.7pg/ml versus 0.02-5.01pg/ml. These markers 
were only found to be efficacious for diagnosis in combination (Linkov et al. 
2008). 
 With detection limit goals indicated by these findings, initial experiments 
will utilize the well and sensor array in conjunction with a standard CHI 660C 
potentiostat. The biomarkers chosen for initial study will be those with the lowest 
detection limit requirements in physiological or disease states, in this case IL-8 
and EGF. Like in the previous studies in this dissertation, EIS impedance will 
initially be used to analyze the systems under study. A concentration gradient of 
purified target samples will be introduced onto sensors immobilized with their 
respective antibodies to determine concentration effects, responsivity and 
sensitivity (Table 6.1a). Controls will include blanks to test for sensor stability. 
Equivalent circuit parameters will be calculated and quantified against the 
concentration of the target (or control). Finally, optimal frequencies will be 
calculated, and the impedances at the respective optimal frequencies of the 
biomarkers over their concentration gradients will be plotted. This study could 
then be repeated for the other two markers (Table 6.1b), and then repeated 
again for all markers with serum components added to test for nonspecific 
binding (Table 6.1c). If optimal frequencies of some antigen-antibody pairs are 
found to be too close to one another, the frequencies could be 'tuned' by 
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 addition of conductive nanoparticles to the antibody prior to immobilization on 
the sensor surface as demonstrated by Ugur Demirok (Demirok 2010). Repetition 
of concentration gradients would be performed (Table 6.1d) to determine and 
refine the 'tuned' frequencies as necessary.  
 With optimal frequencies for biomarker quantification established, 
experiments could be performed utilizing the Zt technique with the constant 
frequency set at said optimal frequencies. First, concentration gradients of the 
first two targets (IL-8 and EGF) will be performed versus their respective 
antibodies (Table 6.1e), with a control of the targets being switched at single 
concentrations, the AC frequency used being held constant on each sensor. This 
experiment will be performed to confirm that a relationship between a 
concentration gradient and resultant impedance will be obtained using Zt, and 
also for the purpose of comparison with impedances obtained previously via EIS. 
Next, at single concentrations to avoid undue experimentation, the biomarkers 
will be tested against their respective antibody at their respective optimal 
frequencies (Table 6.1f), against their nonresepective antibodies at their 
respective optimal frequencies (Table 6.1g), and against their nonrespective 
antibodies at their nonrespective optimal frequencies (Table 6.1h). This will be 
done to assure that undue cross-reactivity is not occurring at the test 
frequencies, i.e. at the nonoptimal frequencies or when appropriate antigen-
antibody combinations are not present, no detection should occur.  
 Next will come simulated multisine experiments. Since no mass-produced 
commercial instrument can perform true multisine Zt, it will be done by continuing 
to use the single frequency Zt transduction technique as done in the previous 
experiments. At a single concentration, a mixture of both antigens will be tested 
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versus sensors with each antibody separately immobilized at the appropriate 
frequencies for the antibodies (Table 6.1i), with control experiments at switched 
frequencies (Table 6.1j). Mirroring this, single sensors immobilized with both 
antibody types will be tested versus single antigen types at a single concentration 
and at the appropriate frequencies for the antigen (Table 6.1k), with control 
experiments at the switched frequencies (Table 6.1l).  Then in addition, single 
sensors with both antibody types immobilized will be tested versus a mixture of 
both antigens at a single concentration, at either frequency (Table 6.1m). These 
experiments will show that the antigens can be detected independently in the 
same solution with the same sensor simply by changing the frequency with which 
the sensor is interrogated. 
 Then a concentration gradient of both antigens, with test concentrations 
chosen with the aid of experiment design software (Design-Expert, Stat-Ease) to 
avoid unnecessary experimentation effort, will be run against sensors 
immobilized with both antibodies on one surface, with optimal frequencies utilized 
at any given point also chosen with the aid of experiment design software (Table 
6.1n). This will be done to demonstrate that a relationship between concentration 
gradients for two antigens in mixed solution and the resultant impedances can be 
obtained by altering the frequency with which the sensor is interrogated, crudely 
simulating a multisine sensor run versus a concentration gradient.  
 In yet another simulated multisine experiment, one concentration of 
mixed-target solutions with serum components added will again be tested versus 
both antibodies immobilized on the sensor. Allowing for sufficient antigen-
antibody association time, the respective optimal frequencies will be used to 
probe the sensor in a time-separated manner (Table 6.1o). Again, interactions 
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from complex solution, nonspecific binding and other factors could possibly 
interfere with the signal, and will specifically be looked for in data analysis. This 
experiment will be repeated with the order of the frequencies switched. 
Combined, this data could be gathered and used to simulate a combined, true 
multisine signal analysis problem utilizing patient samples.  
 Finally, utilizing custom software and hardware, a true multisine, 
simultaneously multiplexing experiment will be performed using both antibodies 
and antigens (Table 6.1p), and the results compared with a concurrent simulated 
multisine experiment (Table 6.1q) for the purpose of ensuring the proper 
operation and efficacy of the multisine potentiostat and software. After this point, 
concentration gradients of biomarkers could be run, the other two thyroid cancer 
biomarkers could be brought back into the study, and further testing using serum 
components to help simulate patient samples could be done. Then the system 
will be ready for testing versus patient samples directly. For example, 'blind' 
solutions (patient or mock-up) could be tested against the sensors to determine 
antigen concentrations based on only the impedances obtained at optimal 
frequencies versus blank solution and the blind solution, and concentrations 
verified via conventional immunofluorescent techniques. The system will also be 
ready for development with other biomarker systems for other diseases and 
disorders.  
 There are many hurdles to pass in the development of a multisine, 
simultaneously multiplexing impedance immunosensor for detecting cytokine 
biomarkers, including extensive experimentation and development of signal 
processing methods. However, with the information provided in the studies 
presented in this work, it is brought that much closer to realization.
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Odyssey Imaging System (Li-Cor), instructions for use 
 Turn on the Odyssey Imaging System by pressing the power button on 
the front panel: . Allow to warm up for at least one minute.  
 Start the Odyssey software in a linked computer. Select the default 
settings and select „OK‟. If creating a new project folder, choose „New‟ from the 
„File‟ drop-down menu. Otherwise, open an existing project folder by selecting 
„Open‟ from the „File‟ drop-down menu. In either case, a new window will open 
where the save location may be changed and the title for the project entered. In 
this window, select „Scan‟. A new window will pop up that indicates where the 
project is stored. Select „OK‟ in this window.  
 At this point, a window will pop up requesting a login and password. Once 
entered, press „OK‟.  
 The „Scanner Console‟ window will open. Here, select the scan area, 
scan resolution, focus offset (the focus depth), and the intensity.  
 Place the item to be scanned in the lower left hand corner of the scan 
surface, before closing the lid of the Odyssey Imaging System.  
 Select „Start Scan‟, and the scan will start, displaying in real time in the 
„Scanner Console‟ window. When it is finished, select the „Save‟ button to save 
the scan, or „Close‟ if not saving the scan. If saving, a new window will pop up 
prompting for a scan title. Press „OK‟ once this information is entered, closing the 
window and reverting the program to its main screen.  
 Select the appropriate scan in the „Scan‟ pane of the main program 
screen. This will reveal an „original analysis‟ icon. Double click this to display the 
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700nm and 800nm images from the scan. The scan components may be viewed 
superimposed or adjacently, and can also have their brightness adjusted.  
 Images may be exported directly by using the „print screen‟ keyboard 
button, or by selecting „Export Image‟ and then „Export Image View‟ from the 
„File‟ drop-down menu. This will open a new window titled „Export View‟.  There, 
the image quality and file format may be selected. Select „Save‟. The window will 
close and the new image saved in the scan folder with its parent.  
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CHI 660c Electrochemical Workstation with CHI 684 Multiplexer, 
instructions for basic experiments (Cyclic Voltammetry, AC Impedance, 
and Impedance – Time) 
 First, the electrochemical system to be examined should be prepared to a 
point where it can be readied for testing quickly. Connect the electrode leads 
from the CHI 684 multiplexer to the electrochemical system. The electrode leads 
should be pre-labeled. Match the working lead with the intended working 
electrode, the reference lead with the intended reference electrode, and the 
counter lead with the intended counter electrode. Note which channel(s) of the 
multiplexer is/are being used. Next, the instruments should be activated, before 
starting the CHI 660c software.  
 Press the „Technique‟ button: . A new window will open for technique 
selection, with a list of available techniques. Among the more used are „Cyclic 
Voltammetry‟, „A.C. Impedance‟, and „Impedance – Time‟.  After selecting the 
preferred technique, hit „OK‟. The technique selection window will close. If a new 
technique was selected, a parameters window will automatically open. If not; 
press the „Parameters‟ button: . A new window will pop up with settings 
pertaining to the technique which was selected. If selecting Cyclic Voltammetry, 
relevant options include the initial voltage (Init E (V)), the maximum voltage (High 
E (V)), the minimum voltage (Low E (V)), the starting scan direction (Initial Scan 
Polarity), the Scan Rate (Scan Rate (V/s)), the number of 1-way sweeps (Sweep 
Segments) and the maximum sensitivity (Sensitivity (A/V).  If selecting A.C. 
Impedance, relevant parameters include the DC offset (Init E (V)), the AC 
frequency range (High Frequency and Low Frequency), and the AC amplitude 
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(Amplitude (V)). If selecting Impedance –Time, relevant parameters include the 
DC offset (Init E (V)), the AC amplitude (Amplitude (V)), the fixed AC frequency 
(Frequency (Hz)), the sample interval (Sample Interval (sec)),  and the running 
time (Run time (sec)). After selecting parameters, press the „OK‟ button, and the 
window will close.  
 On the „Control‟ drop-down menu, select „Multiplexer‟.  A new window 
labeled „Multiplexer‟ will open where multiplexer channels can be selected. Place 
(a) checkmark(s) next to the channel(s) to be used. They will be run in numerical 
order. Press the „Browse‟ button. In the „Save As‟  window that opens, select a 
folder where the data file(s) will be saved and create a base file name. Press the 
save button and the „Save As‟ window will close. On the data files, the channel 
number will be appended to the end of the base filename which was created. 
Finish readying the electrochemical system for testing and press the „Run 
Multiplexer‟ button, which will close the „Multiplexer‟ window and start the 
experiment.  
 A data file with a .bin extension will be created with the data from each 
experiment as each experiment comes to an end. Opening any such file will 
display the data from the experiment in the lower window. To overlay more data 
sets in this graph, in the „Graphics‟ drop-down menu select „Overlay Plots.‟ This 
graph may be copied using the „print screen‟ keyboard button, or by selecting the 
„Graphics‟ drop-down menu and then selecting „Copy to Clipboard.‟ To convert 
the data files to text for further analysis, in the „File‟ drop-down menu select 
„Convert to Text.‟  
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 New experiments may be run with the same parameters simply by re-
entering the „Multiplexer‟ window, changing the filename and channels 
appropriately, and pressing „Run Multiplexer.‟  
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ZSimpWin (EChem Software) 3.21, instructions for data processing.  
 Start by converting the raw CHI .bin data files to be processed into text 
files. Note the folder location of these text files.   
 Open the ZSimpWin program. Once ready, hit the „Open‟ button:  
Next, navigate to the appropriate folder and open a text data file to be analyzed. 
By default, a Nyquist graph of the data will appear in the lower section of the 
program window.    
 By selecting among the chart type buttons, 
various types of charts portraying the data may 
be chosen to appear in the lower section of the program window, including, 
respectively, Nyquist (the default), Bode plots, Real and Imaginary impedance vs 
Frequency, Real vs Imaginary admittance, Capacitance, and Model Error. After 
modeling, these plots will include modeled data points with the raw data points. 
These plots may be copied to the clipboard by selecting the Output drop-down 
menu, then selecting the „copy plot‟ option, or simply by hitting the print screen 
button.  
 By selecting the „Select model and run mode‟ button: , a pop-up 
window will appear prompting the selection of an equivalent circuit model. By 
defaut, within the window, the „Initial values of the parameters‟ should be 
selected as „Auto Setup‟, and the „Run mode‟ should be „Iterate‟. Select the 
model to be tried, and hit the „OK‟ button.  The program will then create a best fit 
to the data using the selected model, which  will appear in the graph area with the 
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original data.  When fitting is done, the prompt, „Want to save results?‟ will 
appear. Answer the prompt by selecting no.  
 Next, select the „Edit parameters and run‟ button: . A new window 
will open.  
Inside, the numbers in the „end‟ collumn correspond to the parameters from the 
best fit equivalent circuit model last run. Under the „Rel. std. error in percents‟ 
collumn is the relative standard error for each term. Also available is the chi-
squared term, and the % that the modeled data at each frequency is off from the 
actual data Z values. This data should be copied manually, as the automatic 
results presentation available within Zsimpwin is not in a format useful for 
analysis software such as Matlab or Excel, and is less time-efficient to use.  
 After copying desired data, hit „Cancel‟. Then open the next text file to be 
analyzed, or change the analysis model as needed.  
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Fig. B.1 Blank Data: (a, b, c) Nyquist plots (real versus imaginary impedance over a frequency 
sweep) of raw data for the blank solution sweeps which form the basis for the blank relative 
standard deviation used to calculate the lower LOD (limit of detection) in section 3.3.2 
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Fig. B.2 IL-2 Raw Data: Nyquist plots (real versus imaginary impedance over a frequency sweep) 
of raw data for the IL-2 EIS-sweep which is shown analyzed in Fig. 3.10, antigen concentrations 
including (a) 0pg/ml (blank solution), (b) 1pg/ml, (c) 5pg/ml, (d) 10pg/ml, (e) 50pg/ml (f) 100pg/ml, 
(g) 500pg/ml, (h) 1000pg/ml, (i) 5000pg/ml, and (j) 10000pg/ml 
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Fig. B.3 IL-10 Raw Data: Nyquist plots (real versus imaginary impedance over a frequency sweep) 
of raw data for the IL-10 EIS-sweep which is shown analyzed in Fig. 3.10, antigen concentrations 
including (a) 0pg/ml (blank solution), (b) 1pg/ml, (c) 5pg/ml, (d) 10pg/ml, (e) 50pg/ml (f) 100pg/ml, 
(g) 500pg/ml, (h) 1000pg/ml, (i) 5000pg/ml, and (j) 10000pg/ml 
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Fig. B.4 IL-12 Raw Data: Nyquist plots (real versus imaginary impedance over a frequency sweep) 
of raw data for the IL-12 EIS-sweep which is shown analyzed in Fig. 3.10, antigen concentrations 
including (a) 0pg/ml (blank solution), (b) 1pg/ml, (c) 5pg/ml, (d) 10pg/ml, (e) 50pg/ml (f) 100pg/ml, 
(g) 500pg/ml, (h) 1000pg/ml, (i) 5000pg/ml, and (j) 10000pg/ml 
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Fig. B.5 IFN-γ Raw Data: Nyquist plots (real versus imaginary impedance over a frequency sweep) 
of raw data for the IFN-γ EIS-sweep which is shown analyzed in Fig. 3.10, antigen concentrations 
including (a) 0pg/ml (blank solution), (b) 1pg/ml, (c) 5pg/ml, (d) 10pg/ml, (e) 50pg/ml (f) 100pg/ml, 
(g) 500pg/ml, (h) 1000pg/ml, (i) 5000pg/ml, and (j) 10000pg/ml 
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Fig. B.6 TNF-α Raw Data: Nyquist plots (real versus imaginary impedance over a frequency 
sweep) of raw data for the TNF-α EIS-sweep which is shown analyzed in Fig. 3.10, antigen 
concentrations including (a) 0pg/ml (blank solution), (b) 1pg/ml, (c) 5pg/ml, (d) 10pg/ml, (e) 50pg/ml 
(f) 100pg/ml, (g) 500pg/ml, (h) 1000pg/ml, (i) 5000pg/ml, and (j) 10000pg/ml 
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Fig. B.7 0% FBS Raw Data: Nyquist plots (real versus imaginary impedance over a frequency 
sweep) of raw data for the IL-12 in 0% FBS EIS-sweep which is shown analyzed in Fig. 3.11, 
concentrations of IL-12 from 0 to 10000pg/ml 
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Fig. B.8 1% FBS Raw Data: Nyquist plots (real versus imaginary impedance over a frequency 
sweep) of raw data for the IL-12 in 1% FBS EIS-sweep which is shown analyzed in Fig. 3.11, 
concentrations of IL-12 from 0 to 10000pg/ml 
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Fig. B.9 100% FBS Raw Data: Nyquist plots (real versus imaginary impedance over a frequency 
sweep) of raw data for the IL-12 in 100% FBS EIS-sweep which is shown analyzed in Fig. 3.11, 
concentrations of IL-12 from 0 to 10000pg/ml 
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Fig. B.10 Impedance-Time Raw Data: Z-t (Impedance versus time) plots of raw data from IL-12 
tested versus various frequencies, some of which is shown analyzed in Fig. 4.10, concentrations of 
IL-12 from 0 to 2500pg/ml 
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APPENDIX C 
ANTIBODY FREQUENCY EFFECT
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Fig. C.1 Antibody Frequency Effect: Nyquist plots are shown for (a) bare electrodes and (b) 
antibody immobilized electrodes including electrodes used for (c) IL-2, (d) IL-10, (e) IL-12, (f) IFN-γ 
and (g) TNF-α. The greatest shift in the frequency spectrum due to antibody immobilization was to 
be found in the range of 5-10Hz, with no significant difference between the different antibodies 
used.  
 
